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 3 
Introduction 
 
Cancer is one of the principal causes of death in the world, and the discover of 
compounds able to kill selectively the affected cells is the main goal for medicinal 
chemists. The treatment given for cancer is highly variable and dependent on a 
number of factors including the type, location and amount of disease and the health 
status of the patient. The treatments are designed to either directly kill/remove the 
cancer cells or to lead to their eventual death by depriving them of signals needed 
for cell division. Other treatments work by stimulating the body's own defenses. The 
treatments may be divided into different categories based on their goal and mode of 
action. Often the different types of treatment are used in combination, either 
simultaneously or sequentially: surgery, radiation, chemotherapy, hormonal 
treatment, targeted therapy, antibodies, immunotherapy, vaccines. 
The research group where I stayed during my PhD have a great and internationally 
recognized experience in the chemotherapy fields, and in the lastest years was 
interested in many different projects: stilbene and rethinoids derivatives, 
antiangiogenic compounds, curcumin analogues, hemiasterlin derivatives. 
In this thesis, two research projects are described. The first is the design and 
synthesis of novel geminal Bisphosphonates to use in the field of immunotherapy; 
the second is the study of new stilbene relates compounds to enhance the 
antiproliferative activity of natural compounds, such as Combretastatin and 
Resveratrol.  
Hence, in these projects we focused our attention in the development of new 
molecules with the aim to discover new potent and no toxic leads to improve 
anticancer therapy. 
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1. Bisphosphonates as inductor of γδ  T lymphocytes 
 
 
Geminal bisphosphonates (BPs) are analogues of endogenous pyrophosphate with P-
C-P backbone instead of P-O-P motif. This substitution makes BPs resistant to 
hydrolysis and allows two additional chains of variable structure. The ability of BPs 
to act with specific molecular targets strictly depends on the BPs structural 
properties. It is well-known that acid phosphonic groups are essential for bone 
mineral, for the capacity to chelate calcium ion, which is further increased by the 
hydroxyl group at side chain on central carbon atom position (“bone hook”)1 (e.g. 
Zolendronate, etc.) 
So far are known three generations of BPs (Figure 1): non-N-containing, N-
containing, and aromatic N-containing bisphosphonates which differ according to 
structure and mechanism of action. 
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Fig 1. The three generation of Bisphosphonates 
 
 
The first generation of BPs consists of molecules with an halogens or linear or non-
linear alkyl in side chain (e.g. Clodronate). These compounds are very similar to 
bone tissue and their mechanism of action consists in the accumulation of cytotoxic 
analogues of ATP in the cells.2 
The second (e.g. Pamidronate) and third (e.g. Zoledronate) generations consist of 
compound with linear or cyclic side chain N-containing (N-BPs). The mechanism of 
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action of these molecules consists in the inhibitions of Farnesyl pyrophosphate 
synthase, an enzyme in the mevalonate pathway.3 The introduction of an aromatic 
N-containing group in side chain (third generation) strongly increases the potency of 
these products, which are the most used BPs in therapy.4 
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1.1 N-containing Bisphosphonates (N-BPs) 
 
Nitrogen-containing bisphosphonates (N-BPs) are important drugs widely used in a 
variety of bone resorption diseases, such osteoporosis, Paget’s disease, and 
hypercalcemya. Some also have antiparasitic and antibacterial activity5. They act by 
inhibiting  the enzyme Farnesyl Pyrophosphate Synthase (FPPS), which plays an 
important role in the mevalonate pathway and in protein prenylation. 
Recently, N-BPs have gained an additional importance as they have shown to inhibit 
tumor cell adhesion, invasion, and proliferation and to induce apoptosis of a variety 
of human tumor cell lines in vitro. More importantly, N-BPs also have shown to 
exhibit direct antitumor activity in vivo by inhibiting cancer growth through 
antiangiogenic, anti-invasive, and immunomodulatory actions.6 Although several 
mechanisms have been proposed to explain the N-BPs’ antitumor effect, the 
inhibition of FPPS surely plays an important role in the reduce prenylation of a 
variety of proteins with mediator functions in signalling cascades such as Ras2 or 
Rho. It also results in the accumulation of isoprenoids, such as IPP (isopentenyl 
pyrophosphate) which induce the expansion of γδ-T cells. Nowadays, there is 
substantial evidence that γδ-T cells possess potent antitumor activity. 
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1.13 Immunotherapy 
 
Immunotherapy is a modern therapy based on the stimulation of immune system to 
treat diseases, especially cancer. The enhanced activity of endogenous molecules 
can be a more efficient and less toxic approach to fight cancer cells. 
Classical immunotherapy consists in the use of monoclonal antibodies.7 Antibodies 
are a key component of the adaptive immune response, playing a central role in both 
in the recognition of foreign antigens and the stimulation of an immune response to 
them. It is not surprising therefore, that many immunotherapeutic approaches 
involve the use of antibodies. The advent of monoclonal antibody technology has 
made it possible to raise antibodies against specific antigens such as the unusual 
antigens that are presented on the surfaces of tumors. A number of therapeutic 
monoclonal antibodies have been approved for use in humans like Bevacizumab, 
Alemtuzumab, Cetuximab, Retuximab, used to treat several kind of tumors such as 
leukaemia, breast, head, neck, colorectal and colon cancer8. 
Radioimmunotherapy involves the use of radioactively conjugated murine 
antibodies against cellular antigens. Most research currently involved their 
application to lymphomas, as these are highly radio-sensitive malignancies. To limit 
radiation exposure, murine antibodies were especially chosen (Ibritumomab 
tiuxetan, Tositumomab) as their high immunogenicity promotes rapid clearance 
from the body9.  
The development and testing of second generation immunotherapies are already 
under way. While antibodies targeted to disease-causing antigens can be effective 
under certain circumstances, in many cases, their efficacy may be limited by other 
factors. In the case of cancer tumors, the microenvironment is immunosuppressive, 
allowing even the tumors that present unusual antigens to survive and flourish in 
spite of the immune response generated by the cancer patient, against his or her own 
tumor tissue. Certain members of a group of molecules known as cytokines, such as 
Interleukin-2 (IL 2) also play a key role in modulating the immune response, and 
have been tried in conjunction with antibodies in order to generate an even more 
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devastating immune response against the tumor10. While the therapeutic 
administration of such cytokines may cause systemic inflammation, resulting in 
serious side effects and toxicity, a new generation of chimeric molecules consisting 
of an immune-stimulatory cytokine attached to an antibody that targets the 
cytokine's activity to a specific environment such as a tumor, are able to generate a 
very effective yet localized immune response against the tumor tissue, destroying 
the cancer-causing cells without the unwanted side-effects.  
In this contest, BPs with an immunostimulatory effect could provide an efficient and 
no toxic alternative to classical imunotherapies.    
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1.14 Farnesyl Pyrophosphate Synthase (FPPS)    
 
The isoprenoid biosynthetic pathway, with over 23000 metabolites, is unrivaled  
elsewhere in nature for the chemical diversity of the compounds it produces. 
Farnesyl pyrophosphate synthase (FPPS) is a key regulatory enzyme in the 
mevalonate pathway11. This pathway, ubiquitous in mammalian cells, provides 
essential lipid molecules, such as cholesterol and isoprenoids, with the latter 
necessary for posttranslational prenylation of small GTPases. In human, Farnesyl 
pyrophosphate is required for the first committed steps in the biosynthesis of 
cholesterol, farnesylated proteins, geranylgeranylated proteins, ubiquinones, 
dolichols, and heme α.12 FPPS catalyzes the sequential condensation of 
isopentenyl pyrophosphate (IPP), first with dimethylallyl pyrophosphate 
(DMAPP) and then with the resultant geranyl pyrophosphate (GPP) to produce 
the C15 farnesyl pyrophosphate (FPP). FPP is a substrate for geranylgeranyl 
pyrophosphate synthase, which produces the C20 isoprenoid geranylgeranyl 
pyrophosphate (GGPP). 
Posttranslational prenylation of small GTPases with FPP or GGPP is crucial 
for their correct subcellular localization and function. 
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Human FPPS exhibits the all α-helical prenyltransferase fold described earlier 
for the avian form of FPPS 13. FPPS is a dimmer with 13 α-helices and 
connecting loops per subunit (Figure 2).  
 
 
 
Fig 2. Farnesyl pyrophosphate structure. 
 
 
Extended loop regions on the top of the protein include those connecting α4–α5 
(residues 107–127) and α8–α9 (residues 249–268). A large central cavity located 
within the helical bundle forms an elongated partly hydrophobic ligand-binding site. 
The bottom of this cavity is delimited by the side chain of Phe-113. Conserved 
aspartate-rich motifs found in helices α4 (103DDIMD107) and α8(243DDYLD247) face 
the central cavity, and a pronounced kink in helix α7 directs the carbonyl of Lys-200 
toward the cavity as well. 
It is now clear that FPPS is the major enzyme target of N-BPs, such as risedronate 
(RIS) and zoledronate (ZOL). 
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1.4  γδ-T cells 
  
γδ T cells represent a minor subset (5-10%) of human peripheral T cells, differing 
from αβ T cells in cell surface phenotype, in limited combinatorial diversity TCR, 
and in human leukocyte antigen-unrestricted antigen recognition. The antigenic 
molecules that activate γδ T cells are still largely unknown. However, γδ T cells are 
peculiar in that they do not seem to require antigen processing and MHC 
presentation of peptide epitopes although some recognize MHC class IB 
molecules14. Furthermore, γδ T cells are believed to have a prominent role in 
recognition of lipid antigens. 
The physiologic function of γδ-T cells remains elusive, though some evidence has 
been accumulated indicating that γδ-T cells play a role in the “first line of defense” 
against a broad spectrum of invasive microorganisms such as mycobacteria. In 
addition, certain hematopoietic tumor cells  (eg. Burkitt lymphoma cell line, Daudi 
or myeloma cell line RPMI 8226) are specifically recognized and lysed by these T 
cells in vitro. In contrast to αβ-T cells, γδ-T cells (Vγ9Vδ2+ subset) recognized 
nonpeptide compounds of low molecular weight (100-600 d) with an essential 
phosphate residue. So far, only one natural ligand has been isolated and 
characterized as isopentenyl-pyrophosphate (IPP). However, γδ-T cells exhibit a 
broad cross-reactivity with a variety of phosphorylated metabolites, such as 
nucleotidic phosphates, phosphorylated sugars, and synthetic pyrophosphates. The 
recognition of ubiquitous nonpeptide antigens by γδ-T cells suggest a surveillance 
function of these T cells for infected or transformed cells. Thus, BPs stimulating 
γδ T cells could strongly improve their immune response effect against tumor and 
infective diseases.15 
Other subsets of γδ-T cells are known as non-Vδ2 T cells and show several 
differences. The extensive structural diversity of Vδ1 and Vδ3 TCRs and the 
existence of Vδ1+ clones reactive against MHC, MHC-like, or non-MHC molecules 
suggest recognition of a highly diverse and heterogeneous set of antigens by non-
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Vδ2 cells, although cognate interactions between non-Vδ2 TCRs and any of these 
antigens have not been shown yet. MHC class-I-chain-related gene A (MICA) has 
also been proposed as an important tumor antigen recognized by Vδ1+ T cells. 
However, the very low affinity of MICA–Vδ1 TCR interactions estimated by 
surface plasmon resonance analyses raises doubts about the functional relevance of 
MICA or MHC class-I-chain-related gene B (MICB) recognition by Vδ1+ TCRs. 
Non-Vδ2 γδ T cells are expanded in various infectious contexts involving 
intracellular bacteria (Mycobacteria and Listeria) as well as extracellular bacteria, 
such as Borrelia burgdorferi and viruses (HIV, cytomegalovirus). In most instances, 
the stimuli that trigger Vδ1 expansion are not derived from pathogens but instead 
correspond to endogenous gene products presumably upregulated on infection. The 
antigens recognized by non-Vδ2 T cells expanded in the above infectious contexts 
have not been characterized, but the fact that Vδ1+ T-cell responses are not blocked 
by monoclonal antibody directed against known classical or non-classical MHC 
molecules suggests recognition of a new class of conserved stress-induced antigens. 
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1.5.  Mechanism of action 
 
Bisphosphonates, in particular nitrogen-containing compounds, are importantly 
drugs widely used in a variety of bone resorption diseases, such as osteoporosis, 
Paget’s disease, and hypercalcemia. Some also have antiparasitic and antibacterial 
activity.  
Geminal bisphosphonates are divided in three generations under structure and 
mechanism of action. 
The first generation of BPs have an halogen or linear/cyclic alkyl on the side chain 
and act by accumulating a toxic analogue of adenosine triphosphate. The resulting 
metabolites contained the P—C—P moiety in place of the β,γ phosphate groups of 
ATP, thus resulting in nonhydrolyzable analogs. 
The second and especially the third generation, nitrogen-containing bisphosphonates 
(N-BPs), act by inhibiting the FPPS. The catalytic site of the enzyme consists of a 
large central cavity formed by mostly antiparallel R-helices with two aspartate-rich 
regions (DDXX(XX)D) located on opposite walls. The aspartates mediate the 
binding of prenyl phosphates to the protein via bridging three Mg2+ ions. On the 
basis of crystallographic and kinetic evidence, two types of mechanisms have been 
proposed, those in which condensation is initiated by heterolytic cleavage of the 
carbon-oxygen bond of the allylic pyrophosphate, yielding a cationic intermediate, 
and those where the formation of the Cl-C4 bond between the two substrates and 
rupture of the C1-oxygen bond is simultaneous through a transition state (TS) with a 
carbocation character (Figure 3). Three conserved residues among different species, 
Thr203, Gln241, and Lys202 have been proposed to stabilize the possible 
carbocation intermediate or transition state. 
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Fig 3. Mechanism of action of N-BPs. 
 
Indeed, the protonated-nitrogen forms of N-BPs closely resemble the cationic 
transition state/reactive intermediate formed during the FPPS catalytic state. This 
inhibition results in the reduced prenylation of a variety of proteins with mediator 
functions in signaling cascades such as Ras2 or Rho. It also results in the 
accumulation of isoprenoids, such as IPP (isopentenyl pyrophosphate), which is the 
only natural ligand isolated inducing expansion of γδ T cells. Different biological 
studies have demonstrated that γδ T cells are effective against different types of 
cancer such as melanomas, renal carcinoma, lymphoma, and multiple myeloma. 
Thus, γδ T cells, or γδ T cells agonists, such as N-BPs, could play a major role in 
controlling human malignancy and could be used therapeutically in combination 
with other anticancer agents. Indeed, clinical studies have recently shown that 
adding immune therapy to classical chemotherapy has survival benefits when 
compared to chemotherapy alone. There is, therefore, major interest in the 
development of novel N-BPs as new promising anticancer agents. 
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1.6.  Novel Aminobisphosphonates 
 
Bisphosphonates are the treatment of choice for diseases that involve excessive bone 
resorption and have been shown to be effective in preventing osteolytic bone disease 
in several different malignancies, including multiple myeloma (MM). Recent animal 
studies have shown that the aminobisphosphonates also have potent antiangiogenic 
activity that may contribute to these drugs’ antibone resorptive effect as well as 
provide additional mechanism by which these drugs may have antimyeloma effects 
as well.  
These drugs were shown to induce expansion of Vγ9Vδ2 T cells in peripheral blood 
mononuclear  cell cultures and enhance cytotoxicity of malignant plasma cells in 
bone marrow cultures by these Vγ9Vδ2 T lymphocytes. Thus, there is  increasing 
evidence that N-BPs can lead direct and indirect effects that result not only in less 
bone loss but also in less tumor mass.  
Confirm this, Wilhem et al. reported of a pilot study of low-dose of interleukin-2 
(IL-2) in combination with pamidronate in patients with low-grade non-Hodgkin 
lymphoma or multiple myeloma.16 They selected 9 patients by positive in vitro 
proliferation of Vγ9Vδ2 T cells in response to pamidronate and IL-2, and show that 
5 of the patients had significant in vivo activation/proliferation of Vγ9Vδ2 T cells. 
Three patients also achieved objective response, indicating that Vγ9Vδ2 T cells 
might contribute to this antilymphoma effect. 
Some of use reported another pilot study of low-dose zoledronic acid in 9 cancer 
patients with bone metastases (3 females affected by breast cancer, 6 males affected 
by prostate cancer; median age, 66 years (54-83 years)17. The aim of this study was 
to evaluate the activity of zoledronic acid (the most representative N-BPs in therapy) 
on identified subsets of Vγ9Vδ2 T cells that display different functional activities: 
CD45RA+CD27+ ,CD45RA-CD27+ and CD45RA-CD27-. The first and the second 
subset, respectively naive and memory cells, strongly proliferate but lack immediate 
effector functions; CD45RA-CD27-, instead, proliferate poorly but produce 
interferon γ (INFγ) and exert cytotoxicity. Both of these functions are strictly 
 16 
involved in their antitumor efficacy. Patients were treated with 4 mg of zoledronic 
acid via 15-minute intravenous infusion every 3 weeks. Peripheral blood 
mononuclear cells (PMBC) were collected before treatment (time 0) and 1 month 
(time 1) and 3 months (time 2) after this administration. The experiment showed that 
zoledronic acid was able as IPP to stimulate Vγ9Vδ2 T cells upon culture in vitro in 
presence of IL2. Treatment with zoledronic acid caused a decrease in the percentage 
of naive and memory cells compared with the control: in the treated cells the 
percentage of these two subsets was 10% of  the whole Vγ9Vδ2 population, while in 
control cell was 70%. The decrease in the percentage of these subsets was 
accompanied by increase of the effector subset, which accounted about 80% of the 
whole Vγ9Vδ2 population after 3 months from the initial treatment with zoledronic 
acid. These results indicated that zoledronic acid in vivo expands the effector subset 
while decreasing the naive and memory subsets with the consequent increase of the 
release of IFNγ and effective antitumor response. 
With these results and consideration in hand we thought to design and synthesize a 
novel class of nitrogen-containing bisphosphonates with the aim to increase the 
immunomodulatory and the antitumoral properties of these compounds.  
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Fig 4. Structure of new N-BPs synthesized. 
 
 
Since zoledronic acid had shown excellent evidences of its properties as Vγ9Vδ2 T 
cells activator and since the administration of zoledronate together IL2 represent a 
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novel, safe, and feasible approach to inducing immunological responses in patients 
with metastatic carcinomas, we thought to develop our new molecules structurally 
related to zoledronic acid. Specifically, we synthesized a small series of new 
dehydroxy-aminobisphosphonates (Figure 4), to verify if the absence of the OH 
group on the central carbon atom were indispensable for biological activity, and if 
these new compounds had less affinity for the bone tissue and were more 
bioavailable. 
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1.7  Chemistry 
 
Bisphosphonates are known by several years, and in literature there are different 
synthesis for the preparation of the various type of compounds (eg. alkylic, cyclic, 
linear, amino, thio-BPs)18.  
For the preparation of our compounds we used a simple and efficient synthetic route 
as shown in Scheme 1. A common starting material, the methylenebisphosphonate 
2, react with the proper heterocyclic nucleophile a-f in THF at reflux. TBD (1,5,7-
triazabicyclo[4.4.0]dec-5-ene) was used as catalyst, but experimental proofs 
demonstrated that the reaction occurs also without the base in good yields. 
Additionally, bisphosphonate derivatives were also prepared heating the solution at 
120°C in a scientific microwave oven for 10 min. The starting material 2 was 
prepared treating paraformaldehyde with diethylamine, and then with commercial 
tetraethyl methylenebisphosphonate 1. The bisphosphonate acid derivatives 4a-f 
were obtained, starting from the correspondent tetraethyl ester 3a-f, by hydrolysis 
with hydrochloric acid or with iodotrimethylsilane. 
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Scheme 1. Reagent and conditions: (i) Et2NH, (CHO)n, pTSA; (ii) Het(a-f), TBD or not; (iii) 
HCl conc.or TMSI.  
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Interesting, compounds 6e-6f, could be in two regioisomeric forms. To establish if 
the reaction was regioselective, and the ratio of the two isomers, these compounds 
had been fully studied by means of NMR techniques by the Department of 
Analytical Chemistry at GlaxoSmithKline in Verona (Italy).  
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Fig 5. Two regioisomers ratio. 
 
Peaks assignments were achieved for both isomers, directly on the 90:10 mixture, 
using gHMQC and gHMBC experiments, while gROESY experiments allowed the 
determination of the chain position (Figure 5). 
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1.8.  Molecular modeling 
 
To design novel compounds, to understand their structure-activity relationship 
(SAR) and confirm their mechanism of action, we conducted some molecular 
modeling studies in collaboration with the Università degli Studi di Napoli Federico 
II (Napoli, Italy). 
In last years, several molecular modeling works had published, about the FPPS, its 
catalytic site, and the interactions of more important BPs, such zoledronate and 
risedronate, with the enzyme. 
Oldfield et al. identified some indispensable features for the activity of BPs on FPPS 
catalytic site: hydrophobic, aromatic, and cationic moieties, together two metal-
binding groups are very important for a bisphosphonate with antitumor activity.19 
We also began with the knowledge of how our lead (zoledronate) binds to the 
FPPS catalytic site. In analyzing the details of the interactions between 
zoledronate and the FPPS catalytic site (PDB codes of the X-ray structures: 
1ZW5, 2F8Z, 2F9K), it emerges that the two phosphonate groups are highly 
important for the binding of zoledronate to the enzyme. The phosphonate groups 
in N-BPs coordinate via Mg ions with the aspartate-rich motifs of the enzyme, 
which are associated with binding the pyrophosphate groups of the allylic 
(DMAP/GPP) substrate. The loss of these interactions either by removal or 
replacement of a phosphonate with other groups leads a huge loss in potency and a 
total abrogation of the ability to hold the enzyme-inhibitor in an isomerized state. 
The anchoring of the bisphosphonate in the active site by the magnesium-dependent 
aspartate-phosphonate interaction is thus a vital component in the inhibitor binding 
and the subsequent isomerisation of the enzyme-inhibitor complex. 
Even the imidazole moiety of zoledronate plays an important role in the binding 
to the enzyme (Figure 6). Indeed, the imidazole in its protonated state mimics 
the carbocation intermediate formed during the catalysis, and the protonated 
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nitrogen makes a double H-bond with the Lys200 carbonyl oxygen and the 
Thr201 side chain (Oγ1).                   
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Fig 6. The protonated state of imidazole mimics the carbocation intermediate in catalytic site. 
 
As a consequence, the only group that could be substituted without a dramatic 
decrease of the FPPS inhibition would be the 1-OH group, which, in the binary 
complex FPPS-zoledronate, forms a water-mediated interaction with Gln240 and 
is also in close proximity to Asp243, which coordinates with magnesium. In 
previous workref, has been shown that the absence of the hydroxyl group at R1 
would therefore appear to initially make the N-BPs better competitive 
inhibitors, able to fit into the open active site more easily. Invariably, the N-
BPs with a hydroxyl are the better final inhibitors, which suggests that 
interactions perhaps mediated by  the hydroxyl further stabilize the isomerized 
state. Also, inspection of the FPPS/ZOL-IPP crystal structure suggests that the 
presence of the hydroxyl group may prove the packing with IPP and that 
compounds lacking a hydroxyl may form a looser ternary complex (eg., would be 
destabilized). 
To test our hypothesis, we performed molecular docking studies of zoledronate and 
1-deshydroxyzoledronate 4a using the FPPS (PDB code: 2F8Z) as receptor (Figure 
7). 
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Fig 7. Docking simulation of compound 4a 
 
As expected, docking calculations provided a binding mode of 4a largely 
overlapping with that of zoledronate. Furthermore, the computed binding free 
energy of 4a, -10.8 kcal/mol, is comparable to that of zoledronate, -9.8 kcal/mol, 
within the statistical error of the algorithm used for docking. The only difference in 
the binding mode of 4a with respect to zoledronate resides in the lack of the 
interaction established by the hydroxyl group, which is absent in our compound. 
If the removal of the C1 hydroxyl group does not substantially influence the 
inhibition of FPPS, it have an important effect of BPs activity in vitro, and 
especially in vivo. In fact, removal of this group should reduce the bone and the 
skeletal retention and should increase exposure of the drug in the peripheral blood 
and in the soft tissue with an increase in the in vitro/vivo antitumor activity. 
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1.9.  Biological Results 
 
The goal of this work is to develop a new series of N-BPs with less bone affinity and 
an increase of efficacy as inductors of γδ T cells compared to bisphosphonates drugs 
in therapy. As seeing above, this stimulation, improving the CD45RA-CD27- subset 
of Vγ9Vδ2 T cells, can increase the concentration in circulating system of IFNγ 
improving the response of these lymphocytes to infections and cancer. Indeed, these 
bioactive compounds can used in immunotherapy, a modern and very important 
branch of antitumor therapy. 
All the synthesized compounds have been tested in a preliminary assay for their 
in vitro bioactivity toward activation-expansion of γδ T lymphocytes. The 
capacity of bisphosphonates to activate, in vitro, human γδ T lymphocytes was 
studied in comparison to zoledronic acid and phosphostim (3), the bromohydrin 
derivative of isopentenyl pyrophosphate, which strongly activates γδ T 
lymphocytes. 
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Fig 8. Zoledronic acid and Phosphostim are strong γδ T lymphocytes activators. 
 
 
Firstly, we conducted a typical dose-response experiment out of seven in which 
peripheral blood mononuclear cells were stimulated in vitro with different 
concentrations of compounds and low doses of IL2 for 7 days. The expansion of 
γδ T cells was calculated and expressed as an expansion factor. 
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At first glance, it is evident that the activity of the compounds is strongly influenced 
by the nitrogens positions in aromatic system. In fact, compound 4b results about 
5000 times less active that 6a. This is completely in line with the theory that 
protonable nitrogen must have a certain distance to geminal carbon atom to properly 
mimic the transition state in the FPPS catalytic cycle (Figure 9).  
 
 
 
Fig 9. Ability of different N-BPs derivatives to expand in vitro human γδ T cells. Peripheral 
blood mononuclear cells were incubated in vitro with different N-BPs derivatives at the 
indicated final concentrations and 20 U/mL final concentration of rIL-2, for 7 days at 37 °C. At 
the end of the incubation period, cells were collected and the γδ T cell expansion factor 
calculated as described in Experimental Section. 
 
In the in vitro FPPS assay, test conducted at the University of Oxford, it becomes 
apparent that the movement of the nitrogen away by the position in zoledronate 
caused a large decrease in potency. Furthermore, the basicity of the nitrogens 
present in the ring also plays a pivotal role in determining the different 
pharmacological profiles of the compounds under study, influencing their strength of 
binding to the enzyme as well as their ability to pass through the cellular membrane. 
In fact, from the enzyme inhibition assays (Table 1), it clearly emerges that 
compounds presenting a more basic nitrogen such as 4a, 4c, and 4d, show lower 
IC50 values. This is probably due to a stronger interaction of the protonable nitrogen 
with the nearby Lys200 and Thr201.
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883.1 ± 71.94f
388.2 ± 16.24e
28.1 ± 2.84d
16.1 ± 1.44c
3069 ± 2644b
9.03 ± 1.84a
4.1 ± 0.2229Zoledronate
IC50 ± SEM (nm)Compounds
 
Table 1. In vitro activity of new N-BPs compared to zoledronate on human FPPS. 
 
However, although the introduction of the purine system in the compounds 4e,f, 
decreases by-around 500 folds the affinity to the enzyme, but the activity on the 
induction of Vγ9Vδ2 T cells is similar to zoledronic acid. These results suggest that 
the introduction of the more lipophilic substituent on the side chain, even if decrease 
the potency to inhibit FPPS of studied N-BPs, enhance their ability to pass cell 
membrane (Table 2).  
 
0.1-0.34f
0.2-0.44e
>104d
1-24c
>104b
0.001-0.0034a
0.1-0.3Zoledronate
1-3IPP
0.015-0.001BrHPP
T lymphocytes
stimulation (!M)
Compounds
 
Table 2. Vγ9Vδ2 T cells stimulation. 
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However, as summarized in Table 2, the most surprising finding is that the 
deshydroxyzoledronate 4a is approximately 100 times more capable of activating 
γδ T lymphocytes with respect to zoledronate, considering that the IC50 for FPPS 
inhibition for 4a is twice that of zoledronate (Table 1). In fact, derivative 4a was 
extremely active in inducing activation of human γδ T lymphocytes upon culture of 
peripheral blood mononuclear cells (PBMC) in the presence of a low dose (20 U/mL 
final concentration) of interleukin (IL)-2. Dose response analysis revealed that 
optimal stimulation and expansion of human γδ T cells occurs at the final 
concentration of 1 nM. In addition, 4a produced a phenotypic switch from naive and 
central memory to effector memory cells, the latter exerting important effector 
functions (such as production of TNF-R and IFNγ and cytotoxicity) against tumor 
cell lines in vitro (data not shown). 
By these experiments, we can defined the mechanism of action of compound 4a. In 
fact, from our initial studies in vitro, we found that activity of compound 4a in 
PMBC cellular line, in association with IL2, was blocked by the presence of 
Mevastatin or Lovastatin (Figure 10). 
 
 
 
Fig 10. Mechanism of action of different N-BPs derivatives on human γδ T cell activation. 
expansion in vitro of γδ T cells was carried out in the presence or absence of mevastatin or 
lovastatin, both used at 1 µM final concentration. 
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In addition, when the above-described in vitro assay is carried out with PBMCs 
depleted of monocytes, the drugs’ effects again disappear (data not shown). With 
these results in hand, we can indicate that compound 4a don’t stimulate directly γδ T 
cells, acting on lymphocytes receptors, but it inhibit the FPPS of macrophages and 
monocytes, that, accumulating and releasing substrates as IPP, induce proliferation 
of  Vγ9Vδ2 T cells effector subset and enhance antitumor response. Indeed, 
compound 4a act as a “third generation” bisphosphonate, although it proved 
considerably more potent that zoledronic acid, the most studied and potent N-BP 
today in therapy. 
To gain better the antitumor activity of our compound 4a, we further investigated 
the antiapoptotic activity on different cell lines and its toxicity on normal and bone 
marrow-derived hematopoietic cells.  
The cytotoxic activity of 4a and of zoledronate was tested on the HUT78 (human T-
lymphoma), K562 (chronic myeloid leukemia expressing the antiapoptotic oncogene 
Bcr-Abl), CCRF-CEM (acute lymphoblastic), CCRFCEM VBL300 (P-glycoprotein, 
multiple drug resistant (MDR) protein expressing acute lymphoblastic) cell lines.  
As shows in Figure 11 our compound 4a was endowed with antiproliferative effects 
and pro-apoptotic activity higher than that of zoledronic acid in both human 
lymphoma HUT78 cells and P-glycoprotein expressing CCRF-CEM VBL300, while 
no significant differences were observed in K562 and CCRF-CEM cells. 
 
 
   
 
Fig 11. (a) Cell growth inhibition induced by different concentration of compound 4a. (b) Cell 
growth inhibition induced by different concentration of zoledronic acid. 
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Moreover, in Table 3, we can see the higher proapoptotic activity of 4a in HUT78 
and CCRF-CEM VBL300 cells, compares to zoledronic acid. We can also note that 
compound 4a was more active than zoledronic acid in the MDRexpressing cells than 
in the parental CCRF-CEM line. As shown in Figure 11a,b and Table 3, zoledronic 
acid and 4a were barely active on Bcr-Abl, expressing K562 cells when used at 
concentrations lower than 50 µM.   
 
 
Cells 4a Zoledronate 
HUT78 40 ± 5.3 24 ± 4.6 
K562 15 ± 3.2 16 ± 5.1 
CEM 22 ± 3.1 20 ± 4.4 
CEMVBL300 37 ± 6.0 22 ± 3.2 
CFU-GM 15 ± 2.2 18 ± 2.7 
 
Table 3. Percentage (±SE=standard error) of Apoptosis Induced by 100 µM compound 4a and 
100 µM Zoledronic Acid. 
 
 
Recent reports indicated that Imatinib mesilate (Gleevec), the reference compound 
for anticancer studies, have a synergistic effect in association to zoledronic acid on 
Bcr-Abl expressing cells.20 With these results in hand, we though to investigate if 
our compound 4a keep this activity. K562 cells were exposed to different 
concentrations of imatinib in combination with 30 µM 4a or zoledronic acid. We 
was pleasantly affected to see that activity of combination of Imatinib  with our 
bisphosphonate was higher than combination with zoledronic acid. 
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Fig 12. Effects of imatinib-zoledronic acid and imatinib-compound 6a combinations in K562 
cells. Cells were incubated with 30 µM zoledronic acid or 30 µM compound 6a in combination 
with concentrations of imatinib ranging from 0.065 to 0.5 µM. After 48 h, the number of living 
cells was determined and expressed as percentage of control.  
 
Additionally, we tested compound 6a and zoledronic acid on normal hematopoietic 
cells CFU-GM proving their absence of toxicity (Figure 13). 
 
 
 
Fig 13. Cytotoxic concentrations of 6a and zoledronic acid don’t change the number of CFU-
GM. 
 
With these good results in hand, we decided to test the antitumor effect of 4a in 
vivo. We investigated the in vivo tumor reactivity of human γδ T cells activated and 
expanded in vitro and then adoptively transferred into SCID mice, according to the 
experimental protocol described by Kabelitz et al.,21analyzing the optimal 
therapeutic efficacy against the breast cancer BT459 cell line. SCID mice were 
conditioned by irradiation and antiasialo-GM1 monoclonal antibody treatment, and 
received at day 0 a single intraperitoneal injection of the breast cancer cell line 
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BT549 (2 × 106/mouse). The high numbers of tumor cells were inoculated to allow 
for fully fledged tumor growth within the period before graft-vs-host reactions 
developed in the SCID mouse reconstituted with human lymphocytes. Mice received 
concomitantly, with the tumor cells, an intraperitoneal injection of human 
recombinant (r)IL-2 (300 ng), or 6a (2 µg), or zoledronate (5 µg), or 4a (2 µg) plus 
rIL-2 (300 ng), or zoledronate (5 µg) plus rIL-2 (300 ng). In addition, mice received 
highly purified human γδ T cells (2 × 107/mouse) where indicated. γδ T cells (2 × 
107/mouse) and zoledronate (5 µg), or 6a (2 µg), were injected every 15 days, while 
(r)IL-2 (300 ng) was given on the same day and at 3 and 6 days after each injection 
of γδ T cells. 
 
 
 
Fig 14. Antitumor effect of 4a and γδ T cells in SCID mice in vivo. SCID mice received a 
single intraperitoneal injection of the breast cancer cell line BT549. Mice 
concomitantlyreceived with the tumor cells an intraperitoneal injection of human recombinant 
(r)IL-2, or 4a, or zoledronate, or 4a plus rIL-2, or zoledronate plus rIL-2. Where indicated, 
mice received highly purified human γδ T cells. 
 
As shown in Figure 14, neither compound 4a nor zoledronic acid or IL 2 alone or in 
combination increase survival time of the mice. This increase when γδ T cells were 
given in association with 4a but not with zoledronic acid or IL 2, however, the 
improvement of survival is not statistically relevant (40 ± 10 versus 28 ± 6). The 
best result was obtained when compound 4a was given together γδ cells and IL2, 
and compares to zoledronic acid in the same association, the increase of survival 
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time was statistically significant (p < 0.05), indicating that 4a is more potent than 
zoledronate in activating and sustaining the antitumor activity of human γδ T cells. 
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1.10.  Conclusions 
 
In this work, we have synthesized a small series of novel geminal bisphosphonates 
with the aim to develop new leads for immunotherapy against cancer. 
Recent data literature showed that N-bisphosphonates, drugs commonly used in 
bone and calcium-correlate diseases for their antiresorptive effect, had an 
stimulating effect on γδ T cells. These lymphocytes subset plays an important role in 
natural immunomodulatory  response to infections and, in particular, cancer. To 
confirm this N-BPs activity, recent in vivo tests demonstrated that zoledronic acid, 
the most used N-bisphosphonate, is able to enhance the effector γδ T cells subset 
and, as consequence, their activity. 
Starting by these results we synthesized our compounds with the aim to increase the 
immunomodulatory effect and, at the same time, to decrease their bone affinity. Our 
synthetic strategy, based on molecular modelling studies, focused on elimination of 
the hydroxyl moiety on central C carbon and insertion of an N-aromatic cyclic side 
chain.  
Hence, our small N-BPs set was tested for its in vitro and in vivo activity. 
Interestingly, one of our compounds, simply the deshydroxy-zoledronic acid (4a) 
showed very exciting results compares to zoledronic acid. In fact, although 4a is less 
affine to target enzyme farnesyl pyrophosphate synthase, demonstrated better γδ T 
cells induction, better cells growth inhibition and apoptotic affect itself and in 
association with Imatinib mesylate (Gleevec), than zoledronic acid. Probably, it is 
due by the absence of the hydroxyl moiety that give zoledronic acid more able to 
interact with FPPS and bone tissue, but at the same time less disposable to peripheral 
blood and soft tissues.  
Also in vivo tests was very interesting, showing that 4a, more than zoledronic acid, 
in association with γδ T cells and IL 2, sensibly enhance the survival time of mice 
after injection of cancer cells. Finally, these very good biological results are 
followed by an important absence of toxicity on normal hematopoietic cells at 
cytotoxic concentration. 
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Thus, taking into account of the unique pharmacological profile of 4a, with a potent 
γδ T cells activation, a remarkable proapoptotic effect both in vitro and in vivo and 
an absolute absence of toxicity, it may be a very interesting anti-cancer drug which 
can be added to immuno-chemotherapy against a wide range of tumor types.  
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1.11.  Experimental Section 
 
Molecular Modeling. Docking Simulations.  
Molecular docking of zoledronate and 6a into the three-dimensional X-ray structure 
of FPPS (PDB code: 2F8Z) was carried out using the AutoDock software package 
(version 4.0) as implemented through the graphical user interface AutoDockTools 
(ADT 1.4.6).20 
 
Ligands and Protein Setup.  
The structures of the inhibitors were first generated from the standard fragment 
library of the SYBYL software version 7.3.21 The docking parametrization of 
ligands, the cofactor isopentenyl pyrophosphate (IPP), and the region of the enzyme 
including the metals and its coordinating ligands (Mg subsite) were performed by 
using the Gaussian03 package22 by applying a full geometry optimization at 
Hartree-Fock level of theory and then calculating the charges using the restrained 
electrostatic potential (RESP) fitting procedure.23,24 For both the optimization and 
the electrostatic potential (ESP) calculation, the locally dense 6-31G* basis set was 
used. The starting geometry of the Mg subsite for ab initio calculations was derived 
by a crystallographic template (PDB code: 2F8Z) including the cocrystallized 
zoledronic acid necessary to get an octahedral coordination of the ions. We treated 
the three magnesium as ions in the +2 oxidation state and with a low spin state (S ) 
0). To properly describe the electrostatic protein environment, the N and C termini 
of the coordinating aspartates were capped with NME and ACE residues, 
respectively. Hence, the system was geometrically optimized by constraining the 
atoms of the backbone of the aspartates and using the previously reported locally 
dense basis set. The model system was then optimized until reaching the default 
Gaussian03 convergence criterion. The RESP charges were then calculated on the 
geometrically minimized ligands, cofactor, and Mg subsite. First, the ESP were 
calculated again by means of the Gaussian package and then the RESP charges were 
obtained by a two-stages fitting procedure,25 fitting first the polar areas by using 
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weak hyperbolic restraints (0.0005 au) and then fitting the remaining areas, 
imposing equivalencies, and by using a stronger hyperbolic restraint (0.001 au). In 
each step, the charges of the standard residues ACE and NME were constrained to 
their AMBER force field value.25 The electrostatic potential used as an input by the 
RESP program was sampled by adapting the Merz-Singh-Kollman scheme,26 
namely using 10 concentric layers at the default level of spacing, a surface density of 
6 points/Å2, and adopting the covalent radius of 0.86 Å for magnesium as reported 
on the WebElements server (Winter M. WebElements Periodic Table; United 
Kingdom: University of Sheffield. http://www.webelements.com/). Hence, the 
computed charges for ligands, cofactor, and Mg subsite were used for further 
docking calculations. 
 
Docking Setup.  
The docking area has been defined by a box, centered on the mass center of the 
cocrystallized zoledronate. Grids points of 40 × 40 × 40 with 0.375 Å spacing were 
calculated around the docking area for all the ligand atom types using AutoGrid4. 
For each ligand, 100 separate docking calculations were performed. Each docking 
calculation consisted of 2.5 × 106 energy evaluations using the Lamarckian genetic 
algorithm local search (GALS) method. A low-frequency local search according to 
the method of Solis and Wets was applied to docking trials to ensure that the final 
solution represents a local minimum. Each docking run was performed with a 
population size of 150, and 300 rounds of Solis and Wets local search were applied 
with a probability of 0.06. A mutation rate of 0.02 and a crossover rate of 0.8 were 
used to generate new docking trials for subsequent generations. The GALS method 
evaluates a population of possible docking solutions and propagates the most 
successful individuals from each generation into the next one. The docking results 
from each of the 100 calculations were clustered on the basis of root-mean square 
deviation (rmsd ) 1.5 Å) between the Cartesian coordinates of the ligand atoms and 
were ranked on the basis of the free energy of binding. 
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Chemistry.  
General Methods and Materials.  
Melting points were obtained in open capillary tubes and are uncorrected. Reactions 
and product mixtures were routinely monitored by thin-layer chromatography (TLC) 
on Merck silica gel precoated F254 plates. Nuclear magnetic resonance (1H NMR, 
13C NMR) spectra were determined in CDCl3 solution unless otherwise indicated 
with a Bruker AC-200 or with Varian Mercury Plus 400 spectrometer, and peak 
positions are given in parts per million downfield from tetramethylsilane as the 
internal standard; J values are expressed in hertz. Compound 4a has been studied 
using a Varian Inova 600 MHz spectrometer in D2O solution. Light petroleum ether 
refers to the 40-60 °C boiling range fractions. Column chromatography was 
performed with Merck 60-200 mesh silica gel. All drying operations were performed 
over anhydrous sodium sulphate. Column chromatography (medium pressure) was 
carried out using the “flash” technique. Microanalysis of all new synthesized 
compounds agreed within ±0.4% of calculated values. The microwave reactions 
were performed in a Discover CEM, which produced controlled irradiation with a 
power of 0-300 W. 
 
Tetraethyl-ethenylidenebisphosphonate. (2). Paraformaldehyde (520 mg, 17.3 
mmol) and diethyl amine (0.36 mL, 3.46 mmol) were combined in 10 mL of 
methanol, warmed until clear, then treated with tetraethylmethylene bisphosphonate 
(0.86 mL, 3.46 mmol) and refluxed for 18 h. The mixture was concentrated in 
vacuo, toluene was then added, and the solvent was evaporated again (2 × 5 mL). 
The residue was dissolved in toluene (20 mL), treated with p-toluensulphonic acid 
(cat.), and refluxed through a Dean-Stark trap for 18 h. The sample was concentrated 
in vacuo, dissolved in chloroform (20 mL), washed with water (10 mL), dried, and 
concentrated in vacuo. The residue oil was used without further purifications for the 
next reaction. Yellow oil; yield: 90%. 
1H NMR δ: 1.17 (t, J=7.2, 12H), 3.90-4.03 (m, 8H), 6.63 (s, 1H), 6.70 (d, J=38, 1H), 
7.10 (d, J =38, 1H).13C NMR δ: 14.5, 62.4, 121.8, 148.2. 
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General Procedures for the Synthesis of Tetraethyl Bisphosphonate 3a-f. 
Method A. A solution of compounds a-f (0.66 mmol) and 2 (200 mg, 0.66 mmol) in 
THF (10 mL) was kept in a microwave vial and heated to 150-160 °C for 15 min in 
a scientific microwave oven. After cooling at room temperature, the solvent was 
evaporated in vacuo, the crude material was dissolved in water (10 mL) and 
extracted with dichloromethane (2 × 15 mL). The organic layers were collected, 
dried, filtered, and evaporated. The crude material was purified by flash 
chromatography on silica gel with dichloromethane-methanol as eluent. 
Method B. A mixture of compounds a-f (0.66 mmol), 2 (200 mg, 0.66 mmol), and 
TBD (88 mg, 0.066 mmol) in THF (15 mL) was stirred under reflux for 4 h, the 
solvent was evaporated in vacuo, and the crude material was dissolved in water (10 
mL) and extracted with dichloromethane (2 × 10 mL). The organic layers were 
collected, dried, filtered, and evaporated. The crude material was purified by flash 
chromatography on silica gel with dichloromethane- methanol as eluent. 
Tetraethyl-[2-(imidazol-1-yl)ethyl]-bisphosphonate (3a). Yield 90%; yellow oil. 
1H NMR δ 1.25-1.34 (m, 12H), 2.40-2.85 (m, 1H), 4.05-4.21 (m, 8H), 4.41-4.59 (m, 
2H), 6.90 (s, 1H), 7.21 (s, 1H), 7.57 (s, 1H). 13C NMR δ 13.4, 45.3, 48.2, 61.3, 
121.7, 126.9, 141.6. 
Tetraethyl-[2-(pyrazol-1-yl)ethyl]-bisphosphonate (3b). Yield 79%; yellow oil. 
1H NMR δ 1.25-1.32 (m, 12H), 3.16-3.43 (m, 1H), 4.02-4.20 (m, 8H), 4.56-4.73 (m, 
2H), 6.17-6.19 (m, 1H), 7.48 (d, J=2.0, 1H), 7.52 (d, J =2.0, 1H). 13C NMR: δ 16.4, 
30.5, 33.8, 37.0, 46.0, 60.4, 105.1, 126.6, 138.8. 
Tetraethyl-[2-(benzoimidazol-1-yl)ethyl]-bisphosphonate (3c). Yield 71%; 
yellow oil. 1H NMR δ 1.20-1.33 (m, 12H), 2.45-2.80 (m, 1H), 4.08-4.20 (m, 8H), 
4.45-4.60 (m, 2H), 7.30-7.42 (m, 2H), 7.83-7.98 (m, 2H), 8.90 (s, 1H). 13C NMR δ 
13.2, 25.3, 34.0, 65.3, 118.4, 125.9, 143.9, 151.5. 
Tetraethyl-[2-(imidazol-2-yl-thio)ethyl]-bisphosphonate (3d). Yield 45%; yellow 
oil. 1H NMR δ 1.24-1.34 (m, 12H), 3.80-3.91 (m, 1H), 4.06-4.28 (m, 8H), 4.36-4.52 
(m, 2H), 6.64 (d, J=2.0, 1H), 6.87 (d, J=2.0, 1H), 11.15 (br, 1H). 13C NMR: δ 16.5, 
33.2, 36.5, 39.7, 42.4, 60.5, 60.7, 121.7, 122.7, 161.7. 
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By means of the procedure utilized, 3e and 3f were obtained as inseparable mixtures 
of regioisomers (ratio 9:1), whose structure was defined by NMR experiments 
carried out on derivative 4e. 
Tetraethyl-[2-(purin-9-yl)ethyl]-bisphosphonate (3e). Yield 48%; yellow oil. 
Main isomer: 1H NMR δ 1.19-1.24 (m, 12H), 3.36-3.53 (m, 1H), 4.06-4.16 (m, 8H), 
4.75-4.83 (m, 2H), 8.17 (s, 1H), 8.95 (s, 1H), 9.11 (s, 1H). 13C NMR δ 13.3, 44.5, 
48.7, 62.0, 133.3, 146.6, 149.6, 150.8, 168.3. 
Tetraethyl-[2-(6-chloro-purin-9-yl)ethyl]-bisphosphonate (3f). Yield 50%; 
yellow oil. Main isomer: 1H NMR δ 1.20-1.24 (m, 12H), 3.35-3.43 (m 1H), 4.01-
4.15 (m, 8H), 4.73-4.84 (m, 2H), 8.0 (s, 1H), 8.22 (s, 1H), 8.71 (s, 1H). 13C NMR δ 
13.0, 41.5, 44.6, 62.3, 133.3, 146.7, 149.5, 150.8, 152.7. 
 
General Procedures for the Synthesis of Bisphosphonic acid 4a-f. 
Method A. A solution of 3a-f (0.25 mmol) in concentrated HCl (3 mL) was stirred 
under reflux for 3 h and the solvent evaporated in vacuo. The residual solid was 
recrystallized from H2O-MeOH to give 4a-f. 
Method B. To an ice-cooled solution of 3a-f (0.25 mmol) in CCl4 (5 mL) was added 
iodotrimethylsilane (0.179 mL, 1.25 mmol) dropwise, and the resulting mixture was 
stirred below 5 °C for 3 h. The reaction mixture was quenched by adding MeOH (10 
mL), and the precipitate was collected and recrystallized by from H2O/MeOH to 
give 4a-f as white or yellow solids. 
[2-(Imidazol-1-yl)ethyl]-bisphosphonic acid (4a). Yield 90%; white solid, mp 
>250 °C dec. 1H NMR (NaOD/D2O) δ 1.83-1.94 (m, 1H), 4.16-4.24 (m, 2H), 6.73 
(s, 1H), 7.09 (s, 1H), 7.57 (s, 1H). 13C NMR (NaOD/D2O) δ 44.3, 47.0, 120.7, 126.9, 
138.8. Anal. (C5H10N2O6P2) C, H, N. 
[2-(Pyrazol-1-yl)ethyl]-bisphosphonic acid (4b). Yield 79%; white solid, mp 199-
202 °C. 1H NMR (NaOD/D2O) δ 2.03-2.24 (m, 1H), 4.27-4.39 (m, 2H), 6.02-6.06 
(m, 1H), 7.29 (s, 1H), 7.59 (s, 1H). 13C NMR: δ 32.3, 35.5, 38.8, 44.7, 105.1, 126.6, 
138.8. Anal. (C5H10N2O6P2) C, H, N. 
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[2-(Benzoimidazol-1-yl)ethyl]-bisphosphonic acid (4c). Yield 67%; white solid, 
mp >250 °C dec. 1H NMR (NaOD/D2O) δ 2.20-2.35 (m, 1H), 4.45-4.58 (m, 2H), 
7.35-7.42 (m, 2H), 7.83-7.98 (m, 2H), 8.72 (s, 1H). 13C NMR (NaOD/D2O) δ 25.3, 
34.0, 118.4, 125.9, 143.9, 151.5. Anal. (C9H12N2O6P2) C, H, N. 
[2-(Imidazol-2-yl-thio)ethyl]-bisphosphonic acid (4d). Yield 40%. 1H NMR 
(NaOD/D2O) δ 2.89-2.98 (m, 1H), 3.99-4.06 (m, 2H), 7.01-7.03 (m, 2H). 13C NMR: 
δ 35.1, 38.3, 41.1, 41.28, 121.7, 122.7, 161.9. Anal. (C5H10N2O6P2S) C, H, N, S. 
[2-(Purin-9-yl)ethyl]-bisphosphonic acid (4e). Yield 55%; yellow solid. Title 
compound was identified by NMR study present as the main isomer (90%). 1H 
NMR (D2O) δ 3.05 (m, 1H), 4.95 (m, 2H), 8.97 (s, 1H), 9.30 (s, 1H), 9.42 (s, 1H). 
13C NMR (150.81 MHz, D2O) δ 42.98, 38.38, 132.42, 140.56, 147.23, 153.35, 
154.75. 
[2-(Purin-7-yl)ethyl]-bisphosphonic acid was found as minor isomer (10%). 1H 
NMR (D2O) δ2.84 (m, 1H), 4.99 (m, 2H), 9.15 (s, 1H), 9.27 (s, 1H), 9.62 (s, 1H). 
Anal. (C7H10N4O6P2) C, H, N. 
[2-(6-Chloro-purin-9-yl)ethyl]-bisphosphonic acid (4f). Yield 59%; yellow solid. 
Main isomer: 1H NMR (NaOD/D2O) δ 2.16-2.32 (m, 1H), 4.32-4.42 (m, 2H), 7.93 
(s, 1H), 7.97 (s, 1H). 13C NMR (NaOD/D2O) δ 41.5, 44.6, 133.3, 146.7, 149.5, 
150.8, 152.7. Anal. (C7H9ClN4O6P2) C, H, N.δ 
 
Biology.  
Expansion in Vitro of γδT Cells.  
Heparinized blood specimens were collected from 12 healthy volunteers (males, age 
range 24-46 years), all working at the Dipartimento di Biopatologia e Metodologie 
Biomediche, University of Palermo, upon informed consent. The study was 
approved by the ethical committee of the University Hospital. Peripheral blood 
mononuclear cells were incubated in vitro with different N-BPs or BrHPP (at the 
indicated final concentrations) and 20 U/mL final concentration of rIL-2, for 7 days 
at 37 °C. At the end of the incubation period, cells were collected and the γδ T cell 
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expansion factor calculated according to our previously published method.27 
Expansion in vitro of γδ T cells, when the mechanism of action of different N-BPs 
was evaluated, was performed as indicated previously, except that the assay was 
carried out in the presence or absence of mevastatin or lovastatin, both used at 1 µM 
final concentration. 
 
In Vivo Antitumor Activity.  
In vivo antitumor activity of γδ T cells was evaluated in SCID mice, using the 
protocol described by Kabelitz et al., with minor modifications.19 Briefly, SCID 
mice (6 mice per group) were conditioned by irradiation (300 rads from a cesium 
source) and antiasialo-GM1 monoclonal antibody (BD Bioscience) treatment. Mice 
received at day 0 a single intraperitoneal injection of the breast cancer cell line 
BT549 (2 × 106/mouse). These high numbers of tumor cells were inoculated to 
allow for full-fledged tumor growth within the period before graft-vs-host reactions 
developed in the SCID mouse reconstituted with human lymphocytes. Mice 
received, concomitantly with the tumor cells, an intraperitoneal injection of human 
recombinant (r)IL-2 (300 ng), or 4a (2 µg), or zoledronate (5 µg), or 4a (2 µg) plus 
rIL-2 (300 ng), or zoledronate (5 µg) plus rIL-2 (300 ng). Where indicated, mice 
received, in addition, highly purified human γδ T cells (2 × 107/mouse). γδ T cells 
(2 × 107/ mouse) and zoledronate (5 µg), or 4a (2 µg), were injected again every 15 
days, while (r)IL-2 (300 ng) was given on the same day and at 3 and 6 days after 
each injection of γδ T cells. *p < 0.02 and **p < 0.005, when compared to all other 
groups. 
 
Cytotoxicity Assays.  
To evaluate the number of live and dead neoplastic cells, the cells were stained with 
trypan blue and counted on a hemocytometer. To determine the growth inhibitory 
activity of the drugs tested, 2 × 105 cells were plated into 25 mm wells (Costar, 
Cambridge, UK) in 1 mL of complete medium and treated with different 
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concentrations of each drug. After 48 h of incubation, the number of viable cells was 
determined and expressed as the percentage of control proliferation. 
 
 
Clonal Assays.  
To evaluate the cytotoxic effects of biphosphonates on normal hemopoietic 
progenitor cells, a clonal assay for CFU-GM (colony-forming units-granulocyte 
macrophage) was performed. Bone marrow mononucleated cells were obtained from 
bone marrow aspirates of five normal volunteers. Bone marrow (3-5 mL) was 
diluted in RPMI 1640, layered over a Ficoll-Hypaque gradient (density, 1.077), 
centrifuged at 400g for 30 min, and the interface mononuclear cells were collected. 
The interface cells were washed three times in PBS, counted, and resuspended at a 
concentration of 1 × 105 in MEM containing 0.9% methylcellulose, 30% FCS, 10-4 
M _-mercaptoethanol, 5% medium conditioned by leukocytes in the presence of 
phytohemagglutinin (PHA-LCM) in 15 mm plastic dishes. After 7 days of culture at 
37 °C in an environment of 5% CO2 and 100% humidity, the number of CFUGM 
was evaluated. 
 
Morphological Evaluation of Apoptosis and Necrosis. 
Drug induced apoptosis and necrosis was determined morphologically after labeling 
with acridine orange and ethidium bromide. Cell (2 × 105) was centrifuged (300g) 
and the pellet was resuspended in 25 µL of the dye mixture. Ten µL of the mixture 
was examined in oil immersion with a 100× objective using a fluorescence 
microscope. Live cells were determined by the uptake of acridine orange (green 
fluorescence) and exclusion of the ethidium bromide (red fluorescence) stain. Live 
and dead apoptotic cells were identified by the perinuclear condensation of 
chromatin, stained by acridine orange (100 µg/ml) or ethidium bromide (100 
µg/mL), respectively, and by the formation of apoptotic bodies. The percentage of 
apoptotic cells was determined after counting at least 300 cells. 
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Determination of Apoptosis by Annexine-V. 
Cells (1 × 106) were washed with PBS and centrifuged at 200g for 5 min. Cell pellet 
was suspended in 100 µL of a staining solution, containing FITC-conjugated 
Annexine-V and propidium iodide (Annexine-V-Fluos Staining Kit, Roche 
Molecular Biochemicals, Mannheim, Germany) and incubated for 15 min at 20 °C. 
The percentage of Annexine-V-positive cells was evaluated by flow cytometry 
(Becton Dickinson). 
 
Determination of Drug Interactions.  
For the determination of the interactions between the drugs, the fractional product 
methods of Webb was applied.28 The predicted values (c) were calculated according 
to the equation c ) a × b/100, where a and b indicate cell survival values with single 
agents. Hence, the combination index (CI) was calculated as the ratio between the 
survival observed with the combinations and the predicted values. The equations CI 
= 1, CI < 1, and CI > 1 indicate additive effects, synergism, and antagonism, 
respectively. 
 
Determination of Inhibition of FPP Synthase.  
FPP synthase was purified and assayed as previously described by Kavanagh et al.29 
Briefly, an expression construct encoding human FPPS (gi 61680822) as N-
terminally His6-tagged fusion protein with a TEV cleavage site was expressed in 
Escherichia coli BL21(DE3). Cells were lysed using a high pressure cell disruptor, 
and the protein was purified to apparent homogeneity using Ni-NTA resin (Qiagen). 
Gel filtration chromatography was then performed using a Superdex 200 column 
(GE/Amersham). For analysis of inhibition, 40 ng (1 pmol) of pure FPP synthase 
was preincubated with N-BP in a volume of 80 µL buffer containing 50 mM Tris 
pH7.7, 2 mM MgCl2, 0.5 mM TCEP, 20 µg/mL BSA for 10 min. Reactions were 
started by the addition of 20 µL of 5× substrate (50 µM GPP and 50 µM 14C-IPP, 
400 KBq/µmol) in water, bringing the inhibitor and substrate to the final desired 
concentrations, and allowed to proceed for an appropriate period of time at 37 °C. 
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Reactions were timed such that a maximum of 10% of the available substrate was 
used. Assays were terminated by the addition of 0.2 mL of conc HCl/methanol (1:4) 
and incubated for 10 min at 37 °C. The reaction mixtures were then extracted with 
0.4 mL of scintillation fluid Microscint E (Perkin-Elmer). After thorough mixing, 
the tubes were briefly centrifuged to separate the two phases and the radioactivity 
was then counted directly using a Microbeta (Perkin-Elmer) scintillation counter. All 
data were fitted to kinetic models using Graphpad Prism. 
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2. Novel Stilbene derivatives as proapoptotic agents 
 
 
The stilbene motif is constituted by two benzene rings link with an ethylenic bridge, 
exists in cis and trans configurations, and it is the core of different biologically 
active natural products, such as Combretastatin, Resveratrol, Arothinoids (Figure 1). 
 
 
OH
OH
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OCH3
OCH3
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Combretastatin CA4 trans-Resveratrol
 
Figure 1. Examples of stilbene in nature. 
 
 
It is known that in nature doesn’t exist the stilbene molecule, but there are about 
thirty different polyhydroxy-derivatives in the Spematophytes kingdom. These 
compounds differs by number, positions, and eventually methylated or glycosylated 
hydroxyl groups. Many of these derivatives are known as Phytoalexins, compounds 
produced by plants under stress conditions, infections or UV irradiations; thus, in the 
past,  they were mainly studied in botanic fields for their anti-fungal activity.  
However, nowadays, after the discovery of a wide range of biologically activities on 
human, the attention of scientific community on stilbenes derivatives is strongly 
growth up.  
The most important and studied natural stilbenes are Resveratrol and 
Combretastatin. 
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2.1. Apoptosis 
 
The natural stilbenes Resveratrol and Combretastatin have in common the skill to 
improve apoptosis in cancer cells. Apoptosis is the process of programmed cell 
death that may occur in multicellular organisms; involves a series of biochemical 
events which leads to a variety of morphological changes, including changes to cell 
membranes, nuclear and chromosomal DNA fragmentation (Figure 1).  
 
 
 
 
Fig 1. The complexity of Apoptosis mechanism. 
 
In contrast to necrosis, which is a form of traumatic cell death that results from acute 
cellular injury, apoptosis, in general, confers advantages during an organism's life 
cycle. Research on apoptosis has increased substantially since the early 1990s. In 
addition to its importance as a biological phenomenon, defective apoptotic processes 
have been implicated in an extensive variety of diseases. The research to induce 
apoptosis is a main goal in development of drugs against cellular proliferation 
diseases, such cancer. 
In healthy conditions, programmed cell death is a needed for proper development, 
such as mitosis, or to destroy cells that represent a threat to the integrity of organism, 
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such as infections, DNA damage, effectors of immune system, cancer. Upon 
receiving specific signals instructing the cells to undergo apoptosis a number of 
distinctive changes occur in the cell. A family of proteins known as caspases are 
typically activated in the early stages of apoptosis. These proteins breakdown or 
cleave key cellular components that are required for normal cellular function 
including structural proteins in the cytoskeleton and nuclear proteins such as DNA 
repair enzymes. The caspases can also activate other degradative enzymes such as 
DNases, which begin to cleave the DNA in the nucleus. There are a number of 
mechanisms through which apoptosis can be induced in cells. The sensitivity of cells 
to any of these stimuli can vary depending on a number of factors such as the 
expression of pro- and anti-apoptotic proteins (eg. the Bcl-2 proteins or the Inhibitor 
of Apoptosis Proteins), the severity of the stimulus and the stage of the cell cycle 
(Figure 2).  
 
 
Fig 2. The main stimuli that can induce apoptosis. 
 
Since the cancer is characterized by an abnormal cells proliferation, the induction of 
apoptosis is an important target for chemotherapy. Natural stilbenes resveratrol and 
combretastatin shows a good activity in this way, prodding us to develop novel 
derivatives to improve anticancer therapy. 
 
 50 
2.2. Resveratrol 
 
Resveratrol (3,4’, 5 trihydroxystilbene) is a naturally occuring phytoalexin produced 
by some spermatophytes, such as grapevines, in response to injury. Given that it is 
present in grape berry skins but not in flesh, white wine contains very small amounts 
of resveratrol, compared to red wine. Resveratrol has been known for centuries in 
Asian medicine as Ko-jo-kon, in the form of the powdered root of Polygonum 
cuspidatum, as an anti-inflammatory drug. Resveratrol displays numerous properties 
related to very different mechanisms of action1. 
However, its interest in the field of cancer therapy is much more recent. In a 
pioneering study, John M. Pezzuto and his colleagues2 reported that resveratrol was 
effective in blocking all three stages (i.e., initiation, promotion and progression) of 
carcinogenesis. Subsequent studies demonstrated that resveratrol exhibited strong 
chemopreventive effects in various experimentally induced tumor models3. The 
compound also inhibited proliferation and induced apoptosis of various cancerous or 
transformed cells, sensitized chemoresistant or radioresistant cancer cells to 
apoptosis, and repressed metastasis. Several recent studies reported that 
intratumoral, peritumoral or intraperitoneal administration of resveratrol 
significantly arrested tumor growth in vivo and induced apoptosis in xenografted 
tumors in athymic nude mice4. 
Inhibition of carcinogenic activation. Several studies have demonstrated that 
resveratrol impairs the carcinogenic activity of polyaromatic hydrocarbons (PAHs), 
which undergo metabolic activation predominantly by CYP enzymes5. The 
transactivation of CYP1A1, which encodes an enzyme frequently involved in 
metabolic activation of a wide spectrum of PAHs, requires the binding of activated 
arylhydrocarbon receptor (AhR) to the promoter segment of the gene. Resveratrol 
strongly inhibit 2,3,7,8-tetrachlorodibenzo-p-dioxin-(TCDD)-induced AhR DNA-
binding activity in human mammary epithelial (MCF-10A) cells. Moreover, 
resveratrol inhibit induction of CYP1A1 expression in rat primary hepatocytes, 
suggesting that the compound acts as an AhR antagonist. resveratrol has been shown 
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to inhibit the activity of CYP1A1, CYP1B1 and CYP1A2 in murine hepatoma 
(Hepa1c1c7) cells, TCDDstimulated mammary epithelial (MCF-10A) cells, DMBA-
treated human breast cancer (MCF-7) cells, and B[a]P-treated human hepatoma 
(HepG2) cells6 . Another member of CYP family is CYP19, alternatively known as 
aromatase, which is a rate-limiting enzyme in the biosynthesis of estrogen. Since 
estrogens play a crucial role in the development of breast cancer, the inhibitory 
effect of resveratrol on the aromatase/CYP19 activity in MCF-7 cells7 suggests that 
the chemopreventive effects of this stilbene compound on mammary carcinogenesis 
are attributed partly to its anti-estrogenic property. 
Induction of carcinogen detoxifying/antioxidant enzymes. Resveratrol enhances the 
expression and/or the activity of phase II anti-oxidant/detoxification enzymes 
including glutathione S-transferase (GST), glutathione peroxidase (GPx), UDP 
glucuronosyl transferase (UGT)-1A, NADPH:quinine oxidoreductase (NQO), heme 
oxygenase-1 (HO-1), glutamate cysteine ligase (GCL), etc.8. Several recent studies 
also demonstrated that the compound induced the protein and mRNA expression of 
HO-1 in human aortic smooth muscle and rat pheochoromocytoma (PC12) cells. 
Moreover, resveratrol restored the cellular glutathione (GSH), which is prone to be 
depleted by cigarette smoke extract (CSE), by inducing GCL-catalyzed GSH 
synthesis in human primary small airway epithelial cells (SAEC) and human 
alveolar epithelial cells (A549)9. By upregulating GCL, resveratrol may have 
rescued these cells from CSE-induced oxidative stress. 
Anti-inflammatory effects: implications for suppression of tumor promotion and 
progression. Chronic inflammation is causally linked to multistage carcinogenesis. 
Mediators of inflammation, such as cyclooxygenase-2 (COX-2), prostaglandins, 
inducible nitric oxide synthase (iNOS), NO, and pro-inflammatory cytokines have 
been involved in carcinogenesis, especially in the promotion and progression stages. 
In addition, pro-inflammatory cytokines, such as interleukin 1 (IL-1), IL-6, IL-8 and 
tumor necrosis factor-α (TNF-α), have also been known to be involved directly or 
indirectly in carcinogenesis10. Thus, components of the inflammatory signaling 
pathways are recognized as potential targets for chemoprevention. Resveratrol 
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exhibited anti-tumor promoting effects by blocking the expression of various 
components of pro-inflammatory signalling, diminished the COX-2 activity and 
reduced the production of PGE2 in peripheral blood leukocytes. The expression of 
pro-inflammatory cytokines appears to be differentially affected by resveratrol. 
While the compound significantly decreased the expression of TNF-a mRNA in 
LPS-activated J774.2 macrophage cells and peripheral blood leukocytes, it failed to 
suppress IL-1b gene expression in J774.2 cells11. However, the inhibition of 
proliferation and induction of apoptosis in human multiple myeloma (MM) cells by 
resveratrol were found to be associated with its interference with signaling pathways 
initiated by IL-1b. 
Induction of cancer cell cycle arrest. The growth of various cancer cells in culture is 
arrested by treatment with resveratrol at different phases of the cell cycle. The 
inhibition of abnormal cell proliferation via modulation of cell cycle progression is 
one of the important strategies for chemoprevention as well as chemotherapy. 
Intracellular signaling pathways, comprised of various cyclins, cyclin-dependent 
kinases (Cdk), Cdk inhibitors, and check point kinases (Chk 1 and Chk 2), are 
involved in fine-tuning of homeostatic maintenance of cell growth and 
differentiation. Therefore, the suppression of abnormal cell proliferation by down-
regulating cyclin-Cdks and/or upregulating Cdk inhibitors may provide an ample 
scope to intervene in the multistage carcinogenesis by dietary phytochemicals. The 
anti-proliferative and growth inhibitory effects of resveratrol have been attributed to 
its ability to block DNA synthesis and interference with various stages of cell cycle 
progression.12 
Induction of apoptosis. The induction of apoptosis selectively in cancer cells is 
regarded as an important strategy for cancer prevention as well as therapy. 
Resveratrol has been reported to induce apoptosis in various cancerous or 
transformed cells in culture, chemically induced mouse skin tumors, and in 
transplanted tumors in nude mice by activating both extrinsic and intrinsic pathways 
of cell death machinery. The induction of apoptosis in human promyelocytic 
leukemia (HL-60) and breast cancer (T47D) cells by resveratrol was mediated via 
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activation of the CD95–CD95L signaling13. Most notably, resveratrol did not affect 
the survival of normal peripheral blood lymphocytes up to 72 h, suggesting that the 
compound induced apoptosis selectively in cancer cells. Resveratrol inhibited 
mitochondrial F1F0-ATPase, an enzyme involved in cellular ATP synthesis, 
providing a possible explanation for resveratrol induced dysfunction of mitochondria 
and induction of apoptosis14. Resveratrol also activated caspase-2 and -8, resulting in 
the processing of down-stream caspases and cell death in a death receptor or 
mitochondria-independent manner. Although resveratrol is a well known anti-
oxidant, the compound was shown to impose both redox and replication stress in 
cells, resulting in senescence-like growth arrest. Heiss et al.15 demonstrated that 
resveratrol generated mitochondria derived ROS in HCT-116 cells and induced 
senescence-like growth arrest by increasing phosphorylation of p53 and elevation of 
the p21 level via activation of p38 MAP kinase and ATM kinase. 
Inhibition of angiogenesis. The disruption of angiogenic signaling cascades 
appeared as a front line of attack by various anti-cancer agents. Due to increased 
metabolic activities and oxygen consumption by rapidly proliferating cells, solid 
tumors are likely to maintain an intratumoral hypoxic environment, which enforces 
tumor cells to adapt by inducing hypoxia responsive genes. Hypoxia inducible factor 
(HIF) acts as a master regulator of cellular oxygen homeostasis by regulating 
expression of hypoxia-responsive genes. Resveratrol has been reported to inhibit the 
expression of HIF-1a and VEGF in OVCAR-3 cells through multiple mechanisms, 
such as inhibition of Akt and MAP kinases, inhibition of protein translational 
regulators, and enhancement of proteasomal degradation of HIF-1a protein.16 
Anti-invasive and anti-metastatic effects. The invasion of tumor cells through tumor-
associated stroma and subsequent metastasis are the central events in neoplastic 
progression. One of the mediators of tumor invasion and metastasis is 
lysophosphatidic acid (LPA), which has been reported to enhance migration of 
human ovarian cancer cells through upregulation of HIF-1a and VEGF. Resveratrol 
significantly attenuated LPA-induced expression of HIF-1a and VEGF, and 
subsequent migration of ovarian cancer cells by blocking activation of upstream 
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ERK1/2 and p70S6 kinase. Resveratrol inibite invasion of various cancer cells by 
reducing the expression and activity of matrix metalloproteinase-2, and by reducing 
the focal adhesion kinase activity.17 
Chemosensitizing effects. Currently, the emergence of resistance to chemotherapy is 
a growing challenge in reducing cancer related deaths worldwide. The use of cancer 
chemopreventive phytochemicals as adjuvants in combination with 
chemotherapeutic agents has been shown to be a pragmatic approach to sensitize 
chemoresistant cancer cells to apoptosis or growth arrest, while minimizing the side 
effects arising from the conventional therapy. As an example, resveratrol enhanced 
the apoptotic effects of bortezomib and thalidomide in multiple myeloma cells. 
Resveratrol, used as a combination therapy with etoposide, inhibited growth and 
induced apoptosis of human colon cancer (HT-29) cells by a ROS-dependent 
activation of adenosine monophosphate (AMP)-activated protein kinase (AMPK). 
These findings suggest that resveratrol, as an adjuvant to chemotherapy, can enhance 
chemosensitvity of cancer cells, while it alleviates unavoidable chemotherapy-
associated adverse effects. P-Glycoprotein, a product of multi drug resistant (MDR)-
1 gene, has been considered as a key player in developing chemoresistance. By 
actively effluxing drugs from cells, P-glycoprotein reduces intratumoral 
concentrations of chemotherapeutic drugs and hence lowers their efficacy. 
Resveratrol was shown to inhibit the P-glycoprotein function and increase 
accumulation of daunorubicin in multidrug resistant KB-C2 cells, thereby 
sensitizing these cells to apoptosis.18 
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2.3. Combretastatins 
 
Isolated in the 80’s from stem wood of the South African tree Combretum caffrum 
combretastatins are low molecular weight molecules containing more oxygenate 
groups substituted benzene rings, but with different structural nature: stilbene 
derivatives as combretastatins A-1 and A-4, dihydrostilbene as combretastatin B-1, 
phenantroquinone as C-1 or macro-lactones as combretastatin  D-1(Figure 3).  
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Fig 3. Natural combretastatins. 
 
All these combretastatin are biologically active, but the best results were obtained by  
Combretastatin A-4 (CA-4), 1b. Combretastatin A4 is an interesting antitumor 
agents and acts ac Vascular Disrupting Agents (VDAs).19 
Vascular targeting strategies can be divided into two different approaches: an 
antiangiogenic approach and so called vascular disrupting approach. Angiogenesis 
inhibitors can be divided into two groups, monoclonal antibodies (Moabs) and small 
molecule tyrosine kinase inhibitors (TKIs). Bevacizumab is a humanised Moab 
targeting VEGF (Vascular Endothelial Growth Factor), which has shown clinical 
activity in combination with cytotoxic chemotherapy in metastatic colorectal cancer, 
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non-small cell lung cancer (NSCLC) and breast cancer. As single agent bevacizumab 
has demonstrated acivity in metastatic renal cell carcinoma.20 Apart from Moabs, a 
large number of small-molecule VEGFR TKIs have been explored in clinical 
studies. Results in randomised studies in renal cell carcinoma with the 
broadspectrum TKIs sunitinib and sorafenib have resulted in their regulatory 
approval for this disease. Theoretically, it is conceivable that angiogenesis inhibitors 
will exert optimal activity in a situation of minimal residual disease with high 
angiogenic potency such as could be the case in the adjuvant setting. 
Vascular disrupting agents (VDAs) target endothelial cells and pericytes of the 
already established tumour vasculature. Selective vascular shutdown suggests a 
structural difference in endothelium of tumour vessels compared to that of normal 
vessels. Indeed, tumour vasculature is, among others, marked by a high rate of 
endothelial cell proliferation, the absence of pericytes, abnormalities in the basement 
membrane and often an increased vascular permeability. Structurally, disorganised, 
tortuous, thinwalled vessels are seen that lack smooth muscle and pericyte coats and 
innervation (Figure 4). 
 
 
 
Fig 4. Architectural difference between vasculature in normal (small arrows) and tumour tissue 
(thick arrows). 
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Vessel diameters are irregular and lengths between branches are long, resulting in a 
high resistance to blood flow. A small decrease in perfusion pressure, which has 
little effect in normal tissue, therefore can be catastrophic to tumours. Finally, 
endothelial cells are highly dependent on tubulin cytoskeleton for their motility, 
invasion, attachment, alignment and proliferation.21 Most VDAs induce changes in 
endothelial cell shape by disruption of the cytoskeleton and cell-to-cell junctions. 
This results in increased permeability to proteins and an increased interstitial fluid 
pressure, which might be sufficient to reduce vessel diameter. Compared to the 
antiangiogenic approach of both TKI and Moab, the vascular disrupting approach 
therefore seems to be cytotoxic rather than cytostatic. However, in preclinical 
models it has been observed that following exposure to a VDA, only the centre of a 
tumour becomes necrotic, with a viable rim (Figure 5) remaining in the periphery. 
This rim of viable tumour cells presumably survives because it derives nutritional 
support (most likely via diffusion) from adjacent normal blood vessels that are 
typically less responsive to VDAs. 
 
 
 
Fig 5. Typical example of a tumour with a viable rim (V) and central necrosis (N) following 
exposure to a vascular disrupting agent. 
 
Vascular disrupting agents have been divided into two types, small molecule (eg 
Combretastatin) and ligand directed VDAs.  
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Small molecule VDAs can be divided into two groups; the tubulin-binding agents 
and the flavonoids. Tubulin-binding agents work by acting at the colchicines-
binding site of the β-subunit of endothelial tubulin, resulting in depolymerisation of 
microtubules and disorganisation of actin and tubulin. Disruption of the endothelial 
cytoskeleton results in conformational changes leading to loss of blood flow. In 
addition to this, a recent study showed that the typical microtubule-destabilising 
agent combretastatin A4 phosphate (CA4P) also selectively disrupts the VE-
cadherin/β-catenin complex interfering with cell–cell contact.22 
Combretastatin A4 phosphate is a water-soluble prodrug of combretastatin A4. 
Following administration, CA4P is rapidly cleaved to CA4 and binds tubulin at or 
close to the colchicines-binding site.23 
Loss of the cell–cell contact increases vascular permeability leading to increased 
interstitial pressure and additional loss of blood flow. In addition to these effects, the 
already mentioned loss of cell–cell contact results in the exposure of the already 
often abnormal basement membrane, which in turn can result in the induction of the 
coagulation cascade with subsequent thrombus formation. Tumour-related 
endothelial cells are much more sensitive to the activity of tubulin-binding agents 
than normal endothelial cells.24 
Thus, these biological results make combretastatin A4 a very interesting starting 
point to develop novel anticancer drugs. 
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2.4. Novel stilbenes derivatives 
 
The research group where I stayed during my PhD has an internationally recognized 
experience on the synthesis of resveratrol and combretastatin derivatives.  
 
HO
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OCH3
H3CO
H3CO
OCH3
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Resveratrol Combretastatin CA4
A A
B
B
 
 
 
Thus, starting from our previous results, to study novel proapoptotic compounds we 
focused the research on two aspects: the synthesis of stilbene derivatives and their 
optimization, based on the substitutions of resveratrol and CA4, and the 
modification of the stilbene motif substituting ethylene bridge with a benzene ring, 
synthesizing novel terphenyl compounds. 
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2.4.1. Chemistry 
 
In a previous work of my research group, it was synthesized and biologically tested 
a Z and E stilbene derivatives set.25 All these compounds were assayed in vitro for 
cell growth inhibition and for their ability to induce apoptosis in HL60 cells 
(myeloblastic acute leukemia). 
0.9 ± 0.10.7 ± 0.090.04 ±0.00450.03±0.0012
15 ± 24 ± 0.38 ± 0.82.5 ± 0.2
8 ± 1.54 ± 0.80.04 ±0.00120.03 ± 0.005
70 ± 8.235 ± 65 ± 0.82 ± 0.4
>20080 ± 1168 ± 5.940 ± 6.1
>20048 ± 8.870 ± 740 ± 5.3
50 ± 8.25 ± 0.9>20042 ± 6.4
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Table 1. The antiproliferative (IC50) and proapoptotic (AC50) activity of trans-Resveratrol and 
their derivatives.  
 
As shown in Table 1, the best result was obtained by cis-derivatives, especially cis-
3’-amino-3,4’,5-trimethoxystilbene and cis-3’-hydroxy-3,4’,5-trimethoxystilbene, 
suggesting that introduction of 3,5 dimethoxy motif may be required for good 
proapoptotic action. 
Starting by these results, to design new compounds we decided to maintain the best 
stilbene A ring (3,5- dimethoxyphenyl) and change the substituents on B ring 
(Figure 1).  
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Figure.1. Structure of new compounds 
 
The synthesis of these derivatives is based on a Wittig reaction between the 3,5-
dimethoxybenzyl-triphenylphosphonium-bromide and the appropriate aldehyde in 
presence of NaH  with tetrahydrofuran as solvent (Scheme 1) giving a 40-60% yield 
and a 1:3 Z/E ratio. 
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Scheme 1. Reagents and conditions: (i) triphenylphosphine, xilene, reflux; (ii) NaH, THF, 
reflux or room temperature. 
 
For the small number of reaction steps and with the aim to develop a more  fast, 
clean and cheap synthetic method we tried to prepare the same compounds using the 
solid phase synthesis (SPS). 
In chemistry, solid-phase synthesis is a method in which molecules are linked on a 
solid support (generally polystyrene resins) and synthesized step-by-step in a 
reactant solution; compared with normal synthesis in a liquid state, it is easier to 
remove excess reactant or byproduct from the desired compound. In this method, 
building blocks are protected at all reactive functional groups. The two functional 
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groups that are able to participate in the desired reaction between building blocks in 
the solution and on the solid support can be controlled by the order of deprotection. 
Indeed, this method is used for the synthesis of peptides, deoxyribonucleic acids, 
and other molecules that need to be synthesized in a certain alignment. Recently, this 
method has also been used in combinatorial chemistry. 
In our first approach we intended to link 3,5-dimethoxy-benzylbromide to 
commercial triphenylphosphine resin synthesizing the phosphonium salt on solid 
support. After washing (using dimethylformamide, methanol, dichloromethane and 
ethyl ether) and drying, the resin was suspended at room temperature for 18h in 
tetrahydrofuran in presence of TBD as soluble base and appropriate aldehyde giving 
the final E/Z stilbenes (Scheme 2). 
 
 
 
 
 
 
 
 
Scheme 2. Synthesis using triphenylphosphine resin. Reagents and conditions: (i) toluene, 
reflux; (ii) TBD, THF, reflux or room temperature. 
 
 
This first approach gave similar results to traditional solution phase synthesis in 
terms of yields and E/Z ratio. Indeed, the use of triphenylphosphine on solid support 
permit to obtained a more clean Wittig reaction due to the absence of 
triphenylphosphine-oxide in solution. However, this method can’t satisfy the aim to 
improve the synthesis of these compounds. 
Thus, we thought that the best approach should be to build the entire stilbene on the 
resin. For this purpose, we had to synthesize the bromo-derivative directly on solid 
support, followed by salt formation, Wittig reaction and, finally, cleavage of the 
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resin to give the clean stilbenes. Since the linkage between 3,5-dimethoxy-benzyl 
bromide or alcohol and resin was difficult, firstly we used the Wang Bromo-resin (p-
hydroxybenzyl-bromide attached on solid support) to investigate if the reaction steps 
occur and give the desired p-hydroxy-stilbenes (Scheme 3). 
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Scheme 3. Approach using Wang-Bromo resin. Reagents and conditions: (i) 
triphenylphosphine, toluene, reflux; (ii) TBD, THF, reflux or room temperature; (iii) TFA, 
CH2Cl2, room temperature. 
 
 
Unexpectedly, the Wittig reaction didn’t occur, when we clove the resin only p-
hydroxybenzyl-triphenylphosphonium bromide was observed. Thus, we tried to 
repeat the synthesis using the Horner-Emmons reaction instead of Wittig reaction, 
but the results was the same (Scheme 4). 
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Scheme 4. The Horner-Emmons approach. Reagents and conditions: (i) triethyl phosphite, 
toluene, reflux; (ii) TBD, THF, reflux or room temperature; (iii) TFA, CH2Cl2, room 
temperature. 
 
Using this method only a compound, trans-4-hydroxy-4’-nitro-stilbene, is observed, 
but in very low yield (about 15%) (Fig.2). 
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Fig.2  trans-4-hydroxy-4’-nitro-stilbene 
 
Probably, this is due to more reactivity of p-nitro-benzaldehyde compares to the 
methoxylated others.  
To compare the yields of solid and solution phase synthesis, we prepared two p-
hydroxy-stilbenes in traditional way (Scheme 5). 
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Scheme 5. Reagents and conditions: (i) benzyl bromide, NaH, acetonitrile, reflux; (ii) NaBH4, 
CH2Cl2; (iii) CBr4, triphenylphosphine, CH2Cl2; (iv) triethyl phosphite, toluene, reflux; (v) 
NaH, THF, reflux 40-50%. 
 
Also in this case, the solution phase yields (about 50%) are better than solid phase, 
resulting not suitable for the preparation of stilbene derivatives libraries. 
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2.4.2. Biological results 
 
In this work, we described the effect of the new stilbene set on the myeloblastic 
leukemia cell line HL60 cells (myeloblastic acute leukemia). Apoptosis was detected 
by morphological examination and confirmed by Annexin V test. In Table 2 are 
reported the antiproliferative (IC50) and apoptosis-inducing (AC50) activities. 
4.8 ± 0.62.5 ± 0.3
6 ± 0.73.5 ± 0.2
5.4 ± 0.42.8 ± 0.470 ± 1037 ± 2.9
2.6 ± 0.31.8 ± 0.2242 ± 6.222 ± 3.7
0.24 ± 0.0170.15 ± 0.014 ± 2.12.5 ± 0.6
28 ± 2.110 ± 1.868 ± 5.635 ± 3
>20042 ± 6.450 ± 8.25 ± 0.9
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Table 2. Antiproliferative and proapoptotic activities of new stilbenes. 
 
As show the most active compounds resulted in the stilbenes 9b, 26a, 26b, 10b, c, d. 
Compounds 9b, 26a, 26b and 10d showed a similar antiproliferative and apoptotic-
inducing activity, a little less than that of compound 10c. Compound 9b showed an 
apoptotic activity about 10–12 times higher than the natural analogues resveratrol 
and piceatannol, and 19 times higher than that of pterostilbene.26 The most active 
compound of this series, however, was 10b, which was about 10 and 17 times more 
active than compounds 10c and 9b. From a structure–activity relationship point of 
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view, remarkable results were obtained when the hydroxyl group of pterostilbene 
was changed to the methoxy derivative 9b, having the latter about 14 times smaller 
IC50. Analogous results were also obtained with the cis-methoxy derivative 10b that 
is about 13 times more active than the corresponding 4’-hydroxy derivative. Of note, 
by locating the methoxy substituent at the 4’-position, as in 9b and 10b, we obtained 
compounds with significantly better activity than the corresponding 3’-methoxy 
derivatives 9d and 10d. 
The effects on cell cycle of the most active cis (10b,c) and trans (9b, 26a) were 
examined by flow cytometry after staining of cells with propidium iodide. HL60 
cells were exposed to each compound at the concentrations reported in Figure 3. 
 
 
 
Fig 3. Flow cytometry analysis of cell cycle. HL60 cells were exposed 24 h to 3.5 µM 9b (b), 
2.5 µM 10c (c), 4 µM 26b (d) and 0.2 µM 10b (e). (a) Control; A, sub-G0–G1 peak. 
 
 
 
In previous studies, we observed that most stilbene compounds cause a block of 
cells in a specific phase of cell cycle, acting as phase-specific drugs; in particular 
many trans-stilbenes (trans-resveratrol and natural resveratrol analogues such as 
piceatannol) induced a prevalent block in S phase, while cis-stilbenes (such as 
combretastatin analogues) in G2–M phase,27 although some trans-stilbenes can still 
cause a block in G2–M.28 Similar to resveratrol, compounds 9b, 26b and 10c 
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induced a partial block of cells in S phase and an apoptotic sub-G0–G1 peak 
corresponding of about 20%, suggesting that these compounds act on HL60 cells as 
phase-specific cytotoxic agents. In contrast, compound 10b caused an evident sub-
G0–G1 peak increase but no modification in cell cycle distribution (phases G0–G1, 
S, and G2–M) respect to the control. 
With the aim to better understand the effect of compound 10b on cell cycle, we 
expose HL60 cells to different concentration of 10b for 24 and 48h. This stilbene 
caused a decrease of G0–G1, S, and G2–M peaks, and a proportional increase of the 
apoptotic sub-G0–G1 peak which was correlated to the time of exposure (24 or 48 
h.) and to the concentration used (Figure 4). These data indicate that the effect of 
10b on HL60 cells is not phase-specific and suggest that 10b could be a compound 
effective in cancers with different kinetics. This is particularly interesting, because it 
could be useful alone or in combination with other anticancer agents to decrease the 
percentage of minimal residual disease caused by kinetic factors. 
 
 
 
Fig 4. Flow cytometry analysis of cell cycle in HL60 cells exposed 24 and 48 h to different 
concentrations of compound 6b. 
 
 
Thus, these results indicate that introduction of methoxy groups at the stilbene motif 
of resveratrol is important to confer cytotoxic and apoptotic activity to this class of 
compounds and, in some cases, the methoxy derivatives were more active than the 
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corresponding phenols. The potent apoptosis-inducing activity and the ability of 10b 
to decrease the number of neoplastic cells in all phases of cell cycle make this 
compound of great interest for further investigations. 
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2.4.3. Experimental Section 
 
Chemistry 
Melting points were obtained with a Kofler apparatus and are uncorrected. 
Reaction courses and product mixtures were routinely monitored by thin-layer 
chromatography (TLC) on silica gel precoated F254 Merck plates. Nuclear 
magnetic resonance (1H and 13C NMR) spectra were determined in CDCl3 
solution, unless otherwise indicated, with a Bruker AC-200 spectrometer, and 
peak positions are given in parts per million downfield from tetramethylsilane 
as internal standard. All drying operations were performed over anhydrous 
sodium sulfate. Column chromatography (medium pressure) was carried out with 
60-200 mesh silica gel, using the flash technique. Microanalysis of all new final 
synthesized compounds agreed with calculated values within ± 0.4% of the 
theoretical. 
 
3,5-Dimethoxybenzyltriphenylphosphonium bromide (7a). A solution of 
triphenylphosphine (1.76 g, 6.72 mmol, 1.6 equiv.) in xylene was added to a 
solution of 3,5-dimethoxybenzyl bromide (1 g, 4.2 mmol, 1 equiv.) in xylene 
and the reaction was stirred under reflux overnight. After cooling to room 
temperature the reaction was filtered. The solid was washed with diethyl ether and 
recristallyzed from methanol/diethyl ether to give white needles. Yield 95%. mp 
265-267 °C. 
 
General Procedure for the Stilbene Syntheses. To the phosphonium bromide  (7a, 
1 eq) in anhydrous tetrahydrofuran at 0°C was added NaH (1.5 eq), and the resulting 
yellow solution was stirred under argon for 15-30 min. A solution of the appropriate 
aldehyde (8a-d, 1.2 eq) in tetrahydrofuran was added dropwise and the mixture 
stirred for 2-15 h. The resulting suspension was diluted with ethyl ether and washed 
with water and brine. After drying on anhydrous sodium sulphate, removal of the 
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solvent in vacuo afforded a tan oil. The oil was separated by flash column 
chromatography (hexane/ethyl acetate). The cis-stilbene eluted first as a clear oil 
followed by the trans isomer as a colorless solid or oil. 
 
3,5-Dimethoxy-4’-nitrostilbenes (9a, 10a). Obtained from 3,5-
dimethoxybenzyltriphenylphosphonium bromide (7a, 200 mg, 0.4 mmol) and 4-
nitrobenzaldehyde (8a, 54 mg, 0.36 mmol) with NaH (10 mg, 0.43 mmol). 
Purification and separation by flash chromatography (petroleum ether/diethyl ether 
9:1). Cis/trans ratio: 1:2. Total yield 45%. 
Trans (9a). Orange solid. M.p. = 132-135°C. 1H-NMR (CDCl3, 200 MHz): δ 3.84 
(s, 6H), 6.46 (t, J = 2.4, 1H), 6.69 (d, J = 2.4, 2H), 7.11 (d, J = 16, 2H), 7.20 (d, J = 
16, 2H), 7.63 (d, J = 9.2, 2H), 8.22 (d, J = 8.8, 2H). 13C NMR (CDCl3, 200 MHz): 
δ 55.6, 99.5, 109.5, 124.7, 126.4, 129.0, 138.3, 138.6, 143.4, 147.2, 161.9.  
Cis (10a). Orange solid. M.p. = 70-72°C. 1H-NMR (CDCl3, 200 MHz): δ 3.61 (s, 
6H), 6.28 (m, 3H), 6.53 (d, J = 12, 1H), 6.69 (d, J = 12, 1H), 7.34 (d, J = 8.8, 2H), 
8.02 (d, J = 8.8, 2H). 13C NMR (CDCl3, 200 MHz): δ 55.8, 98.5, 109.8, 125.7, 
127.4, 129.0, 138.3, 138.9, 145.0, 147.2, 161.8.  
 
3,4’,5-Trimethoxy stilbenes (9b, 10b). Obtained from 3,5-
dimethoxybenzyltriphenylphosphonium bromide (7a, 200 mg, 0.4 mmol) and p-
anisaldehyde (8b, 50 mg, 0.36 mmol) with NaH (10 mg, 0.43 mmol). Purification 
and separation by flash chromatography (petroleum ether/diethyl ether 9:1). 
Cis/trans ratio: 1.5:2. Total yield 35%. 
Trans (9b). Light yellow solid. M.p. = 55-56°C. 1H-NMR (CDCl3, 200 MHz): δ 
3.82 (s, 9H), 6.37 (t, J = 2.2, 1H), 6.65 (d, J = 2.2, 2H), 6.89 (d, J = 8.8, 2H), 6.89 
(d, J = 16, 1H), 7.04 (d, J = 16, 1H), 7.44 (d, J = 9, 2H). 13C NMR (CDCl3, 200 
MHz): δ 54.9, 55.6, 99.5, 109.5, 114.7, 126.4, 128.3, 129.6, 138.3, 138.6, 160.1, 
161.9. 
Cis (10b). Yellow oil. 1H-NMR (CDCl3, 200 MHz): δ 3.66 (s, 6H), 3.77 (s, 3H), 
6.31 (t, J = 2.2, 1H), 6.43 (d, J = 2.2, 2H), 6.43 (d, J = 12.2, 1H), 6.53 (d, J = 12.2, 
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1H), 6.76 (d, J = 8.8, 2H), 7.20 (d, J = 9.2, 2H). 13C NMR (CDCl3, 200 MHz): 
δ 54.3, 55.6, 98.9, 110.1, 115.2, 126.4, 128.0, 129.2, 137.9, 159.7, 161.9.  
 
3,3’,4’,5,5’-Pentamethoxy stilbenes (9c, 10c): Obtained from 3,5-
dimethoxybenzyltriphenylphosphonium bromide (7a, 553 mg, 1.12 mmol) and 
3,4,5-trimethoxybenzaldehyde (8c, 200 mg, 1.02 mmol) with NaH (29 mg, 1.22 
mmol). Purification and separation by flash chromatography (petroleum 
ether/diethyl ether 8:2). Cis/trans ratio: 1:3. Total yield 38%. 
Trans (9c). Light yellow solid. M.p. = 136-138°C. 1H-NMR: δ 3.82 (s, 6H), 3.86 (s, 
3H), 3.91 (s, 6H), 6.39 (t, J = 2.2, 1H), 6.66 (d, J = 2.2, 2H), 6.73 (s, 2H), 6.91 (d, J 
= 16.4, 1H), 7.02 (d, J = 16.2, 1H). 13C-NMR: δ 55.4, 56.2, 61.0, 100.0, 103.7, 
104.5, 128.2, 129.2, 132.9, 138.1, 139.3, 153.5, 161.1.  
Cis (10c). Yellow oil. 1H-NMR: δ  3.67 (s, 12H), 3.81 (s, 3H), 6.31 (t, J = 2.2, 1H), 
6.44 (d, J = 2.4, 2H), 6.50 (s, 4H). 13C-NMR: δ  55.3, 56.0, 61.0, 99.8, 106.2, 106.7, 
130.0, 130.5, 139.3, 152.9, 160.7.  
 
3,3’,5-Trimethoxy stilbenes (9d, 10d): Obtained from 3,5-
dimethoxybenzyltriphenylphosphonium bromide (7a, 200 mg, 0.4 mmol) and m-
anisaldehyde (8d, 50 mg, 0.36 mmol) with NaH (10 mg, 0.43 mmol). Purification 
and separation by flash chromatography (petroleum ether/diethyl ether 95:5). 
Cis/Trans ratio: 1.5:2. Total yield 45%. 
Trans (9d). Light yellow solid. M.p. 59-63°C. 1H-NMR (CDCl3, 200 MHz) δ 3.84 
(s, 9H), 6.40 (t, J = 2.2, 1H), 6.67 (d, J = 2.2, 2H), 6.79-6.85 (m, 1H), 7.04 (s, 3H), 
7.08-7.12 (m, 1H), 7.23-7.27 (m, 1H).13C-NMR (CDCl3, 200 MHz): δ 55.3, 55.4, 
100.1, 104.7, 111.8, 113.5, 119.4, 129.0, 129.2, 129.7, 138.6, 139.3, 160.0, 161.0. 
Cis (10d). Yellow oil. 1H-NMR (CDCl3, 200 MHz): δ  3.64 (s, 6H), 3.68 (s, 3H), 
6.31 (t, J = 2.2, 1H), 6.42 (d, J = 2.4, 2H), 6.52 (d, J = 12.2, 1H), 6.59 (d, J = 12.2, 
1H) 6.71-6.88 (m, 3H), 7.11-7.19 (m, 1H). 13C-NMR (CDCl3, 200 MHz): δ 55.2, 
55.3, 99.9, 106.8, 113.4, 113.9, 121.6, 129.2, 130.5, 130.6, 138.6, 139.1, 159.4, 160. 
6.  
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4-(Benzyloxy)benzyl alcohol (21): A solution of benzaldehydes 20 (10 mmol) in 
THF (25 ml) was added dropwise to a well-stirred suspension of sodium 
borohydride (10 mmol) in THF (50 mL). The reaction mixture was stirred at room 
temperature for 4 h and then quenched by the dropwise addition of water (10 mL). 
The resulting reaction mixture was passed through a Celite pad. The filtrate was 
dried over anhydrous sodium sulphate, and the solvent was evaporated to give the 
corresponding alcohols 21 as white needles. Yield 92%: 1H NMR (CDCl3, 200 
MHz) δ 2.70 (br s, 1H), 4.49 (s, 2H), 5.03 (s, 2H), 6.92 (d, J= 8.3 2H), 7.20 (J = 8.3 
2H), 7.40 (m, 5H). 
 
4-(Benzyloxy)benzyl bromide (22): Phosphorous tribromide (10 mmol) was added 
to a well-stirred solution of benzyl alcohol 21 (10 mmol) in dry methylene chloride 
(45 ml) at 0 °C under argon. The stirring was continued for 2 h at 0 °C and at room 
temperature for 1 h. The reaction mixture was poured onto ice-water (200 ml), 
warmed, and extracted with diethyl ether. The ether layers were combined and dried 
over anhydrous sodium sulphate. Evaporation of the solvent gave the respective 
bromides 22 as white needles. (yield 92%). 1H NMR (CDCl3, 200 MHz) δ 4.49 (s, 
2H), 5.06 (s, 2H), 6.95 (d, J = 8.3, 2H) 7.37 (d, J=8.3, 2H), 7.40 (m, 5H). 
 
Diethyl [4(benzyloxy)benzyl]phosphonate (23): Freshly distilled triethyl 
phosphate (2.49 g, 15 mmol) was added to the benzyl bromides 22 (10mmol) 
containing a catalytic amount of tetrabutylammonium iodide, and the resulting 
mixture was heated at 110-130 "C for 10 h. Excess triethyl phosphite was removed 
by heating for 3 h at 55 "C under vacuum (0.5 mmHg) to yield the resulting 
phosphonate esters 23 as yellow oil (yield 94%). 1H NMR (CDCl3, 200 MHz) δ 1.26 
(t, J = 7.4, 6H), 3.08 (d, J=1.6, 2H), 3.99 (quint, J= 7.4, 4H), 5.02 (s, 2H) ,6 .89 (d, 
J= 8.3, 2H), 7.41 (d, J= 8.3, 2H), 7.5 (m, 5H). 
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General procedure for the preparation of stilbenes 25a,b: To a solution of 4-
Benzyloxybenzylphosphonic acid diethyl ester (23, 1 equiv) in dry tetrahydrofuran, 
NaH (2 equiv.) and aldehyde 24a,b (1 equiv.) were added at 0°C and the solution 
stirred at room temperature overnight. The reaction was quenched with water and 
poured into a water/ice mixture and extracted with ethyl acetate. The organic phases 
were collected, washed with brine and dried over anhydrous sodium sulphate. After 
removal of the solvent the crude material was purified by chromatography giving 
only trans isomers 25a,b.  
25a: Yield 35%. Colourless solid. M.p. = 144-147°C. 1H-NMR (CDCl3, 200 MHz): 
δ  2.27 (s, 3H), 2.29 (s, 3H), 5.09 (s, 2H), 6.93 (d, J=16.4, 1H), 6.96-6.99 (m, 2H), 
7.02 (d, J=16.4, 1H), 7.11 (d, J = 8, 1H), 7.22-7.28 (m, 2H), 7.32-7.46 (m, 7H).  
25b: Yield 42%. Colourless solid. 1H-NMR (CDCl3, 200 MHz): δ 2.16 (s, 3H), 2.24 
(s, 3H), 4.98 (s, 2H), 6.64-6.67 (m, 2H), 6.92 (s, 1H), 7.03-7.17 (m, 9H), 7.40-7.44 
(m, 2H). 
 
General procedure for the cleavage of the benzyl group (Stilbenes 26a,b): N,N-
dimethylaniline (3.0 equiv.) was added to a stirred solution of 25a,b (1.0 equiv.) in 
dry methylene chloride under a argon atmosphere at 0°C. After 5 min, anhydrous 
AlCl3 (4.0 equiv.) was added in one portion. After 2-8 h, the reaction mixture was 
cooled and a 5% HCl acqueous solution was added. The resulting mixture was 
extracted with ethyl acetate, and the combined extracts were washed with brine. 
Removal of solvent in vacuo from organic phase yielded the crude hydroxystilbene 
26a,b, which were purified by flash chromatography (petroleum ether/ethyl acetate) 
26a: Yield 53%. Red solid. M.p. = 150-153°C. 1H-NMR (CDCl3, 200 MHz): δ 2.27 
(s, 3H), 2.29 (s, 3H), 4.76 (s, 1H), 6.82 (d, J = 8.6, 2H), 6.92 (d, J = 16.4, 1H), 7.00 
(d, J = 16.4, 1H), 7.10 (d, J = 8, 1H), 7.22-7.27 (m, 2H), 7.39 (d, J = 8, 2H). 13C-
NMR (CDCl3, 200 MHz): δ 19.6, 115.6, 123.8, 126.8, 127.0, 127.6, 127.8, 130.0, 
135.3.  
26b: Yield 55%. Colourless solid. 1H-NMR (CDCl3, 200 MHz): δ 2.16 (s, 3H), 2.24 
(s, 3H), 6.50 (bs, 1H), 6.63 (d, J=2.82, 2H), 6.92-7.12 (m, 5H), 7.45 (d, J=1.88, 2H). 
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13C-NMR (CDCl3, 200 MHz): δ 19.5, 115.5, 124.4, 127.8, 128.2, 130.1, 134.7, 
135.0, 135.9, 136.3, 157.2.  
 
General procedure for the preparation of the stilbenes in solid phase 
(triphenylphosphine resin method, Scheme 2). 
To a suspension of commercial triphenylphosphine polymer bound (11, 1 equiv.) in 
dimethylformamide, 3,5-Dimethoxybenzylbromide (7a, 3 equiv.) was added, and the 
mixture was stirred at 100°C for 16 h. The reaction was filtered and the resin was 
washed with water, dimethylformamide, methanol, dichloromethane, diethyl ether 
and dried. The resulting derivatized resin was suspended in dry tetrahydrofuran (1 
equiv.), TBD (3 equiv.) and aldehydes (8a-d, 3 equiv.) were added. The mixture was 
stirred under reflux for 16 h, then filtered and washed with methanol and methylene 
chloride. After removal of the solvent the crude material was purified by flash 
chromatography to give cis 10a-d and trans 9a-d stilbenes. Yields are calculated on 
loading of triphenylphosphine into the resin starting material. 
Compounds 9a, 10a: reaction of 3,5-dimethoxybenzyltriphenylphosphonium 
bromide polymer bound (180 mg, 0.18 mmol der., 1 equiv.) and 4-
nitrobenzaldheyde (82 mg, 0.54 mmol, 3 equiv.) in presence of TBD (75 mg, 0.54 
mmol, 3 equiv.). Cis/trans ratio: 1:3. Total yield 29% 
Compounds 9b, 10b: reaction of 3,5-dimethoxybenzyltriphenylphosphonium 
bromide polymer bound (400 mg, 0.4 mmol der., 1 equiv.) and p-anisaldehyde (163 
mg, 1.2 mmol, 3 equiv.) in presence of TBD (167 mg, 1.2 mmol, 3 equiv.). Cis/trans 
ratio: 1.5:2. Total yield 15%. 
Compounds 9c, 10c: reaction of 3,5-dimethoxybenzyltriphenylphosphonium 
bromide polymer bound (400 mg, 0.4 mmol der., 1 equiv.) and 3,4,5-
trimethoxybenzaldehyde (235 mg, 1.12 mmol, 3 equiv.) in presence of TBD (156 
mg, 1.12 mmol, 3 equiv.). Cis/trans ratio: 1:2.5. Total yield 34%. 
Compounds 9d, 10d: reaction of 3,5-dimethoxybenzyltriphenylphosphonium 
bromide polymer bound (580 mg, 0.58 mmol der., 1 equiv.) and m-anisaldehyde 
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(237 mg, 1.74 mmol, 3 equiv.) in presence of TBD (242 mg, 1.74 mmol, 3 equiv.). 
Cis/trans ratio: 1.5:2. Total yield 30%. 
 
Preparation of 4-hydroxy-stilbene 5g in solid phase (Wang-bromo resin 
method, Scheme 4). 4-Benzyloxybenzylphosphonic acid diethyl ester polymer 
bound (18): To a suspension of commercially available (4-Benzyloxybenzyl)-
bromide polymer bound (13, 1 equiv.) in toluene triethyl phosphite was added (3 
equiv.) and the mixture was stirred under reflux for 16 h. Then, the derivatized resin 
was filtered and washed with water, dimethylformamide, methanol, dichloromethane 
and diethyl ether and dried. 
 
(E)-4-Hydroxy-4’-nitrostilbene (26a): to a suspension of (4-Benzyloxybenzyl)-
phosphonic acid diethyl ester polymer bound (18, 1 equiv.) in dry tetrahydrofuran, 
TBD and p-nitrobenzaldehyde (8a) were added and the reaction was stirred at reflux 
for 16 h. The mixture was filtered and washed with water, dimethylformamide, 
methanol, dichloromethane, diethyl ether and dried. The resulting derivatised resin 
was stirred in a solution of trifluoroacetic acid/dichloromethane 65:35 for 3 h at 
room temperature. After filtration, the resin was washed with methanol and 
methylene chloride and the solvent was evaporated in vacuo. The resulting crude 
material was purified by chromatography on silica gel. 
Purification by flash chromatography (petroleum ether/ethyl acetate 9:1). Yield 50 
% of red solid.  
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Biology  
Cells. Continuous neoplastic cells HL60 (myeloblastic acute leukemia) were grown 
in RPMI 1640 (Gibco Grand Island, NY, USA) containing 10% FCS (Gibco), 100 
U/mL penicillin (Gibco), 100 µg/ml streptomycin (Gibco), and 2mM L-glutamine 
(Sigma Chemical Co, St Louis, MO) in a 5% CO2 atmosphere at 37 °C. 
Cytotoxicity assays. To evaluate the number of live and dead neoplastic cells, the 
cells were stained with trypan blue and counted on a hemocytometer. To determine 
the growth inhibitory activity of the drugs tested, 2x105 cells were plated into 25 mm 
wells (Costar, Cambridge, UK) in 1 mL of complete medium and treated with 
different concentrations of each drug. After 48 h of incubation, the number of viable 
cells was determined and expressed as percent of control proliferation.  
 
Morphological evaluation of apoptosis and necrosis. Drug induced apoptosis and 
necrosis was determined morphologically after labelling with acridine orange and 
ethidium bromide. Cells (2x105) were centrifuged (300 g) and the pellet was 
resuspended in 25 µL of the dye mixture. Ten µL of the mixture was examined in oil 
immersion with a 100x objective using a fluorescence microscope. Live cells were 
determined by the uptake of acridine orange (green fluorescence) and exclusion of 
ethidium bromide (red fluorescence) stain. Live and dead apoptotic cells were 
identified by perinuclear condensation of chromatin stained by acridine orange (100 
µg/mL) or ethidium bromide (100 µg/mL), respectively, and by the formation of 
apoptotic bodies. The percentage of apoptotic cells was determined after counting at 
least 300 cells. 
 
Determination of apoptosis by Annexine V. Cells (1x106) were washed with PBS and 
centrifuged at 200 g for 5 minutes. Cell pellets were suspended in 100 µL of staining 
solution containing FITC-conjugated Annexine-V and propidium iodide (Annexine-
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V-Fluos Staining Kit, Roche Molecular Biochemicals, Mannheim, Germany) and 
incubated for 15 minutes at 20 C°: Annexine V positive cells was evaluated by flow 
cytometry Becton Dickinson, San Jose, CA). 
 
Flow cytometry analysis of cell cycle and apoptosis. Cells were washed once in ice-
cold PBS and resuspended at concentration of 1x106/mL in a hypotonic 
fluorochrome solution containing propidium iodide (Sigma) 50 µg/mL in 0.1% 
sodium citrate plus 0.03% (v/v) nonidet P-40 (Sigma). After 30 minutes of 
incubation, the fluorescence of each sample was analysed as single-parameter 
frequency histograms by using a FACScan flow cytometer (Becton Dickinson). The 
distribution of cells in the cell cycle was analysed with the ModFit LT program 
(Verity Software House, Inc) and apoptosis was determined by evaluating the 
percentage of hypoploid nuclei accumulated in the sub-G0-G1 peak after labeling 
with propidium iodide.  
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2.5. Development of stilbenes optimization 
 
In this PhD thesis and in previous works of my research group are described 
different series of stilbene derivatives with proapoptotic activity. The best results 
were obtained by cis-3,4′,5-trimethoxy-3′-aminostilbene (27, and in previous works 
called 5c, Figure 4).  
 
 
OCH3
H3CO
NH2
OCH3
27 (5c)
 
Figure 4. cis-3,4′,5-trimethoxy-3′-aminostilbene: the best candidate for optimization 
 
This compound shows a proapoptotic activity and is a colchicine site microtubule 
inhibitor,25 is highly potent against various tumor cells and blocks cell cycle 
progression in G2-M phase; is tolerated in mice up to 100 mg/kg, and no major 
organ toxicity was observed. In particular, there was no bone marrow toxicity, and 
the ability of bone marrow engraftment was not affected by stilbene 5c treatment.29 
Stilbene 5c can selectively suppress tumor vascular perfusion without damaging 
normal vascular perfusion in a DCE-MRI study. Most importantly, mice treated with 
5 daily injection of stilbene 5c did not show any compromise in heart function, 
suggesting that stilbene 5c may be superior to existing VDAs by it low cardiac 
toxicity. Thus, we selected this derivative as lead compound to optimize for further 
investigations.   
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In this purpose, we tried to improve two aspects of our lead, the biological activity 
and water solubility. In our previous study29, stilbene 5c was made as an HCl salt 
form to enhance water solubility, which was sufficient to carry out animal 
experiment but it is still an issue for drug formulation.  
We used two approach to optimize the stilbene 5c: the first was computer-based 
drug design and synthesis of other derivatives; the second was to make prodrugs as 
it was done in ZD6126 and CA4P. Both of them are attached to a phosphate group to 
make a prodrug to enhance their water solubility, and the added phosphate group 
could be activated by removing the phosphate group.30 Prodrugs are 
pharmacologically inactive drug derivatives that must undergo a chemical or 
biochemical transformation in order to be active in the body and exert the desired 
pharmacological effect of the parent drugs. Conversion to the active drugs can occur 
before, during or after absorption, or at any specific site in the body. The major goal 
in designing prodrugs is to overcome the various physicochemical and 
pharmacokinetic limitations of the parent drugs which compromise their clinical 
application. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 81 
2.5.1. The first approach: computer-based drug design 
 
With the aim to design the new derivatives we started by docking model of stilbene 
5c into tubulin, observing that there is enough space in the colchicine binding pocket 
to accommodate a molecular design in the neighbor of the amino group. Thus, We 
converted the amino group and the methoxyl groups of the phenyl ring into a 5-atom 
ring structure to make into a pyrrole or imidazole ring. Combined with the existing 
benzyl ring, they will make a structure of indole or benzimidazole. The advantage of 
this modification is to remove the methoxy group that is highly hydrophobic. The 
added nitrogen allows formation of a hydrogen bond withVal-315 of tubulin (Fig. 
5), which may potentially enhance the binding affinity and improve water solubility. 
We also added a methyl group to the nitrogen of the indole or benzimidazole to 
recapitulate the methoxy group and compare their biological activity with their 
parent molecules without methyl group. If the addition of methyl group lead to a 
better biological activity, it would suggest that the hydrophobic interaction in this 
pocket is absolutely essential. 
 
         
NOCH3
H3CO
R
N
OCH3
H3CO
R
28a R=H
28b R=CH3
29a R=H
29b R=CH3
N
NOCH3
H3CO
R
30a R=H
30b R=CH3
 
                        a                                                          b 
Fig. 5. a Computer based design and synthesis of stilbene derivatives. b Structures of the six 
new derivatives. 
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These compounds were synthesized by classical Wittig reaction (Scheme 3): 
 
OCH3
H3CO
PPh3
Br
X
N
R
Y
Q
     a: R=H, X=C,Y=CHO, Q=H
     b: R=CH3, X=C, Y=CHO, Q=H
     c: R=H, X=C, Y=H, Q=CHO
     d: R=CH3, X=C, Y=H, Q=CHO
     e: R=H, X=N, Y=CHO, Q=H
     f:  R=CH3, X=N, Y=CHO, Q=H
(i) 28a,b
29a,b
30a,b
31a-f
7a
 
Scheme 3. Synthesis of optimized compounds. 
 
 
Thus, we tested the new compounds in UCI-101 ovarian cancer cells, MDAMB231 
ovarian cancer cells and MiaPaCa2 pancreatic cancer cells. IC50 of each compound 
was determined using Alamar Blue staining and the results were very similar among 
the three cells. 
 
 
Fig.6  
Compound IC50 (nM) Compound IC50 (nM) Compound IC50 (nM) 
28a 250 29a 250 30a 260 
28b 60 29b 200 30b 80 
Table 3. IC50 against UCI-101 ovarian cancer cells. 
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The compounds with a methyl group exhibited a better biological activity compared 
with those without methyl group (Table 3). The compound with the methyl group at 
the cis side of the molecule has a better cytotoxic activity compared with that with 
methyl group at the trans location. Addition of second nitrogen to make into 
benzimidazole rather than indole does not change the biological activity. Similar 
studies were performed in other cell lines, including MDA-MB231 breast cancer 
cells, MiaPaCa2 pancreatic cancer cells and A549 non-small cell lung cancer cells 
and the results are similar. However, water solubility of compounds with or without 
a methyl group turns out to be worse than stilbene 5c and not optimal for further 
development. 
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2.5.2. The second approach: synthesis of prodrugs 
 
With the aim to improve water solubility of stilbene 5c we choose to synthesize 
some its prodrug derivatives. This was the strategy used to solve the water solubility 
problem of CA4 and ZD6126 by adding a phosphate group. Different water soluble 
side chains were added through two different linkages with the free amino group of 
stilbene 5c. The side chains used for enhancing water solubility are a morpholino 
group linked to the amino group by either carbamate (PD7) or urea (PD6) linker, 
and a triethylene glycol linked by carbamate linker (PD5) (Fig. 7). 
 
OCH3
H3CO
R=
N
H
N
O
O N
O
O
OH
O
2
OCH3
N
H
R
O
PD5
PEG-carbamate
PD6
Morpholino-urea
PD7
Morpholino-carbamate
HCl
27
 
 
Fig 7 Structure of synthesized prodrugs derivatives 
 
The synthesis of these new compounds was conducted as shown in Scheme 4. 
Stilbene 5c was firstly reacted with one equivalent of trichloroethyl chloroformate in 
dioxane at 60°C for 3 h to give a crude isocyanate. To the latter crude isocyanate 
solubilized in dry dioxane, the appropriate nocleophile was added portionwise. The 
reaction was heated at 60°C for 12 h. After cooling down to room temperature, the 
mixture was concentrated in vacuo and the residue was purified by flash 
chromatography on silica gel to afford expected derivative. 
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Scheme 4. Reagents and conditions: (i) Trichloromethyl chloroformate, dioxane, 60°C, (ii) 
triethylen glycol or 4-aminoethyl-morpholine or 4-hydroxyethyl-morpholine, dioxano, 60°C, 
(iii) HCl/Ethyl acetate or HCl/Methanol or HCl 10% in aqueous solution. 
 
 
Then, to hydrochloride formation, the free bases were treated with a solution of 
chloridric acid in ethyl acetate or methanol to prevent the carbamate or urea 
hydrolysis; however, the derivatives stability was maintain also using an aqueous 
solution.  
These three prodrugs were tested in UCI-101 cells for their IC50 in vitro. Only PD7 
was active in suppressing growth of tumor cells at a concentration of 3 µM, which is 
100 times higher than the active form stilbene 5c. Both PD5 and PD6 were not able 
to induce significant killing even at concentration up to 3 µM, suggesting that their 
activity is inferior compared with PD7 (Fig. 8). 
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Fig 8. Cell cycle effect of PD7 on UCI-101 cells. 
 
This could be due to the fact that prodrugs may not be converted into the active form 
stilbene 5c in tissue culture condition, and the intact prodrugs could never be fit into 
the colchicine-binding pocket due to their bulky side chains added for improving 
water solubility. Incubation of the three prodrugs with serum for 1 h followed by 
addition into the culture cells was not able to enhance their activity, suggesting that 
the prodrug conversion is dependent on the presence of cells.  
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With these results in hand, we decided to perform further studies on PD7. In order to 
test whether PD7 induces cell death through the same mechanism as its active form 
stilbene 5c, cell cycle analysis in UCI101 cells was done after cells are treated with 
stilbene 5c or PD7. At 1 µM PD7 had no effect in cells cycle progression. At 3 µM 
(IC50), PD7 induced significant G2/M arrest and a subG1 population that represents 
cell death. Further increase of PD7 concentration to 10 µM leads to near complete 
cell death. These findings are very similar to what we observed with stilbene 5c 
except that higher concentrations (100 folds higher than stilbene 5c) of PD7 were 
required (Fig. 9). 
 
 
Fig.9 Suppression of tumor growth by prodrugs. 
 
To get a better assessment of mitotic arrest by either agent, cells treated with either 
stilbene 5c or PD7 were stained with phospho-histone 3b, a mitotic marker. The 
result showed an increase in the positive stained cells after either treatment (Fig. 10), 
confirming the mitotic arrest shown in cell cycle analysis. 
Same studies was done in other tumor cells including A549 lung cancer, MDA-
MB231 breast cancer, HCT116 colon cancer cells with similar IC50. 
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Fig.10 Immunofluorescence staining of mitotic cells. 
 
After these tests, we investigate the effects of our prodrug on microtubule pattern. 
Because UCI-101 cells have scant cytoplasm and not ideal for examination of 
tubulin, MDAMB231 breast cancer cells were used instead and treated with 
vincristine, stilbene 5c, CA4 or PD7. Microtubule in cells treated with all 
microtubule inhibitors exhibited a disrupted pattern compared with a fine reticular 
network in control cells (Fig. 11).  
 
 
 
Fig 11. Disruption of microtubule 
 
 89 
Thus, both PD7 and stilbene 5c are tubulin inhibitors, and are expected to disrupt 
mitotic spindle formation and stop cell cycle progression in the G2/M stage, as 
shown in flow cytometry studies. It is interesting that when cells was treated with 
PD7 showed multiple microtubule organization centre, which was not seen in cells 
treated with other microtubule-interfering agents, probably due to prodrug nature of 
this compound and a slow release of active drug. 
To carry on our study, we investigate the signalling pathway in cells after PD7 
treatment analyzing cell lysates by western blotting using antibodies against various 
kinases. UCI-101 cells were treated with stilbene 5c (100 nM), PD7 (3 µM) or CA4 
(10 nM) and harvested at a time course (0, 4, 8, 16, and 36 h) for this study. 
Phosphorylation of Cdc2, a kinases controlling cell cycle progression, was 
significantly suppressed after incubation with PD7 for 36 h (Fig. 12).  
 
 
Fig.12. Signaling events induced by various anti-mitotic agents 
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The total Cdc2 protein level also decreased at 36 h, but not as prominent. This 
finding is consistent with the cell cycle arrest in mitotic phase after treatment 
(Figure 2b). Similar finding was seen in cells treated with stilbene 5c and CA4. The 
phosphorylation status of MAPK, Chk1 and Chk2 was investigated next. 
Phosphorylation of Chk2 appears to increase after cells were treated with any of the 
three agents, and the effect of PD7 appears most prominent. No significant 
difference was detected in total protein or phosphorylation status of MAPK and 
Chk1. Total protein level of p53 did not change in the first 16 h after treatment but 
increased dramatically at 36 h. Examination of phosphorylation of ser15, ser20, and 
ser46 in p53 showed that ser46 exhibited a transient increase at 16 h but then back to 
baseline at 36 h. Finally the total amount of aurora B kinase has a same transient 
increase at 16 h as phosphorylation of p53 at ser 46. 
Thus, with the aim to confirm the conversion of PD7 in 5c, we started a set of  in 
vivo tests. Firstly, we injected PD7 (100 mg/kg) intravenously into BALB/c mice, 
collected blood in three different time points, and, after separation and analysis by 
LC/MS/MS, we saw that the improvement of concentrations ratio of 5c versus PD7 
was about 4.7% during the time, confirming the prodrug nature of PD7. Thus, we 
investigated its tolerability in mice. Since PD7 is fully water soluble, it was 
dissolved in normal saline and injected intravenously into BALB/c mice at the same 
dose of 100 mg/kg. Mice tolerated the same dose well without any evidence of 
toxicity. When the dose of PD7 was increased to 330 mg/kg, mice died at 3rd day, 
indicating that the maximal tolerated dose is in the 100–330 mg/kg range.  
The in vivo efficacy of PD7 was then investigated using nude mice with tumor 
xenograft derived from UCI-101 cells. Mice with tumor xenografts were treated 
with stilbene 5c, PD5 or PD7 at 25 mg/kg by intraperitoneal injection three times a 
week for total 7 doses and compared with control group treated with normal saline. 
Tumor sizes were calculated by the long and short axes. Mouse weight and behavior 
did not suggest any sign of toxicity. Neither stilbene 5c nor PD5 showed any tumor 
growth suppression when mice were treated by a schedule of three times a week. 
There was 20–30% tumor growth suppression in mice treated with PD7 (Fig 12).            
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Fig.12. a) Suppression of tumor growth by single agent. b) No weight change after treatment. 
 
With these results in hand we can assert that this derivative had a marginal benefit in 
therapy used a singlet agent. Thus, we started to study the its biological activity in 
association with other drugs. At this purpose we chose Bevacizumab (monoclonal 
antibody, a VEGF) as ideal candidate; in fact, this strategy has previously been 
successfully with stilbene 5c and is based based on the rationale that VDAs induce 
tumor hypoxia and release of VEGF to mobilize bone marrow endothelial progenitor 
cells for repair. Addition of a VEGF inhibitor could potentially prevent the effect 
due to the surge of VEGF after VDAs treatment. Mice were treated with PD7 
intraperitoneally at 25 mg/kg per day 5 days a week with or without bevacizumab 
intravenously at 10 mg/kg twice a week. Each group had 8 mice for statistical 
analysis. Treatment was continued for 2 weeks. Tumor growth was evaluated by 
measuring the long and short axes to calculate the volume. In this set of experiment, 
PD7 by itself had a very weak effect compared with the control group and show 
minimal benefit in suppressing tumor growth. Mice treated with bevacizumab along 
showed a tumor growth suppression of about 60%. Mice treated with combination of 
PD7 and bevacizumab showed a robust tumor growth suppression up to 80%, 
indicating that PD7 have a synergistic effect with bevacizumab similar to stilbene 5c 
(Fig. 13). 
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Fig. 13. Synergistic effect of PD7 and bevacizumab. 
 
Thus, in this thesis work, we developed an optimization of a stilbene derivative with 
strong activity, but low solubility and some undesired effect. We used two different 
approaches, the first was based on computer design, and the elimination of a 
methoxyl group enhance the water solubility, decreasing, however, the biological 
activity. The second approach was based on the preparation of prodrugs derivatives, 
a successful strategy for CA4P and ZD6126. In these cases the addition of phosphate 
group enhance the solubility and lead these drugs to finish the phase I clinical trials, 
rendering the CA4P and ZD6126 the most advanced agents in clinical development 
as VDAs for cancer therapy. 
Here, instead of phosphate group, we chose an urea and two carbamates linkages, 
and the best results was obtained by a morpholino-carbamate group that solve 
completely the problem of solubility. The product PD7 is completely water soluble, 
which will greatly help drug formulation. The carbamate can be hydrolyzed to 
release the morpholino group in a cell-dependent manner because incubation with 
serum for 1 h before adding to tissue culture cells did not change the biological 
activity of PD7. The biological activity of PD7 was 100 folds less effective in vitro 
but has a similar potency compared to stilbene 5c in tumor xenografts. We also 
confirmed that PD7 can be converted into stilbene 5c, although the ratio between 
stilbene 5c and PD7 is about 5%. PD7 may have another advantage in slower release 
of active stilbene 5c to further minimize any potential side effect. The carbamate 
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linkage can be hydrolyzed in circulation without enzymatic reaction, the byproduct 
morpholino group is a small molecule and is expected to be excreted in kidney in a 
short period of time.  
The cell cycle analysis and microtubule staining assays proved that PD7 and stilbene 
5c have similar mechanism of action in disrupting microtubule. We did notice a 
minor difference in one of the PD7 treated cells, which shows multiple microtubule 
organizing centers. The significance of this finding is not clear, perhaps it is due to 
lower activity in inducing microtubule depolymerization without affecting the 
proliferation of organization centers. Several cell signalling mediators are all similar 
in their changes after treatment with 5c and its prodrug. These findings support that 
the effect of PD7 is mediated by its conversion into active stilbene 5c to suppress 
mitotic spindle formation. 
The biological activity of PD7 by itself is not very active similar to stilbene 5c in 
barely suppressing tumor growth. However, similar to the situation of stilbene 5c, 
the effect is much more robust when combined with the VEGF inhibitor 
bevacizumab. The reason for the synergistic effect between PD7 and bevacizumab 
should be similar to that of stilbene 5c. PD7/stilbene 5c induces tumor hypoxia by 
damaging tumor vasculature. The hypoxia environment in tumor lead to production 
of VEGF to induce proliferation and mobilization of bone marrow endothelial 
progenitor cells, which will be responsible to home in tumor vessels that are stripped 
off endothelial cells to reestablish tumor vasculature. Blocking the effect of VEGF 
will prevent the surge of endothelial progenitor cells immediately after PD7/stilbene 
5c administration and enhance the therapeutic efficacy of PD7/stilbene 5c. 
Finally, The fact that PD7 is not active by itself could a potential benefit of PD7 in 
cardiac toxicity noted in many other VDAs. Although animal study of stilbene 5c 
did not reveal any compromise in cardiac function after daily IP injection for 5 
days31, stilbene 5c is still a potent cell death inducer of human umbilical vein 
endothelial cells (HUVECs). This means that stilbene 5c in circulation could still 
have the potential to induce normal endothelial damage. 
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Thus, the prodrug PD7 in a soluble form and slow conversion, could strongly 
decrease the undesired side effects of stilbene 5c, improving their activity. Hence, 
PD7 can be a very attractive candidate for further clinical and pre-clinical 
investigations in cancer therapy. 
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2.5.3. Experimental section 
 
General procedure for the synthesis of stilbenes 28-30a,b and trans isomers. 
To a solution of opportune aldehyde  (31a-f, 2 mmol) in 10 mL of anhydrous THF, 
the appropriate phosphonium salt 7a (2,2 mmol) was added in one portion. The 
suspension was cooled in an ice bath and NaH was added (50% in mineral 
suspension, 2.2 mmol). The reaction mixture was then stirred at room temperature 
for 24 h, filtered on a Celite bed and washed with THF. After solvent evaporation, 
the residue was solubilized with methylene chloride (15 mL) and washed with water 
(5 mL) and brine (5 mL), then dried and evaporated again. The residue was purified 
and the mixture of Z and E isomers separated by flash chromatography on silica gel. 
(Z)-6-[2-(3,5-Dimethoxyphenyl)-ethenyl]-1H-indole (28a). Eluent: Diethyl ether–
light petroleum 3:7; Yield 29%. 1H NMR (CDCl3, 400 MHz) δ: 3.61 (s, 6H), 6.31 (t, 
J=2.4, 1H), 6.47–6.51 (m, 4H), 6.72 (d, J=12.4, 1H), 7.08 (dd, J=1.6, J=8.0 1H), 
7.17–7.18 (m, 1H), 7.32 (s, 1H), 7.49 (d, J=8.0 1H), 8.05 (br, 1H). 13C NMR 
(CDCl3, 400 MHz) δ: 55.3, 99.8, 102.7, 106.8, 111.4, 120.3, 121.6, 124.9, 127.3, 
128.7, 131.8, 139.9, 160.6. Anal. Calcd for C18H17NO2: C, 77.40; H, 6.13; N, 5.01. 
Found: C, 77.24; H, 6.12; N, 4.99. 
(Z)-6-[2-(3,5-Dimethoxyphenyl)-ethenyl]-1-methylindole (28b). Oil, 270 mg. 
Yield 30% 1H NMR (CDCl3, 400 MHz) δ: 3.62 (s, 6H), 3.68 (s, 3H), 6.33 (t, J=2.2, 
1H), 6.41 (d, J=3.2, 1H), 6.45 (d, J=3.2, 1H), 6.50–6.54 (m, 3H), 6.74 (d, J=12.0, 
1H), 7.02 (d, J=3.2, 1H), 7.09 (d, J=8.4, 1H), 7.46 (d, J=8.4, 1H). 13C NMR (CDCl3, 
400 MHz) δ: 32.7, 55.3, 99.8, 100.0, 101.0, 106.8, 109.8, 120.3, 121.0, 128.6, 129.5, 
131.9, 139.9, 160.6. Anal. Calcd for C19H19NO2: C, 77.79; H, 6.53; N, 4.77. Found: 
C, 77.93; H, 6.55; N, 4.76. 
(Z)-5-[2-(3,5-Dimethoxyphenyl)-ethenyl]-1H-indole (29a). Eluent: Diethyl ether–
light petroleum 3:7; Yield 27%. 1H NMR (CDCl3, 400 MHz) δ: 3.61 (s, 6H), 6.31 (t, 
J=2.4, 1H), 6.43–6.49 (m, 3H), 6.73 (d, J=12.2, 1H), 7.13–7.18 (m, 3H), 7.24 (d, J= 
8.8 1H), 7.60 (s, 1H), 8.10 (br, 1H). 13C NMR (CDCl3, 400 MHz) δ: 55.2, 99.7, 
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102.9, 106.8, 110.6, 121.5, 123.5, 124.5, 127.9, 128.1, 128.8, 132.0, 135.1, 139.8, 
160.5. Anal. Calcd for C18H17NO2: C, 77.40; H, 6.13; N, 5.01. Found: C, 77.15; H, 
6.13; N, 5.00. 
(Z)-5-[2-(3,5-Dimethoxyphenyl)-ethenyl]-1-methylindole (29b). Oil, 274 mg. 
Yield 28%. 1H NMR (CDCl3, 400 MHz) δ: 3.63 (s, 6H), 3.76 (s, 3H), 6.32 (t, J=2.2, 
1H), 6.40–6.43 (m, 2H), 6.46–6.52 (m, 2H), 7.73 (d, J=12.2, 1H), 7.0 (d, J=2.2, 1H), 
7.17–7.19 (m, 2H), 7.58–7.59 (m, 1H). 13C NMR (CDCl3, 400 MHz) δ: 33.0, 55.4, 
99.7, 101.3, 104.7, 106.7, 108.8, 121.7, 123.0, 127.8, 129.1, 132.0, 139.9, 160.5. 
Anal. Calcd for C19H19NO2: C, 77.79; H, 6.53; N, 4.77. Found: C, 77.95; H, 6.50; N, 
4.76. 
(Z)-5-[2-(3,5-Dimethoxyphenyl)-ethenyl]-1H-benzoimidazole (30a). Eluent: 
Diethyl ether–light petroleum 3:7; Yield 25% 1H NMR (CDCl3, 400 MHz) δ: 3.04 
(br, 1H), 3.61 (s, 6H), 6.31 (t, J=2.2, 1H), 6.41 (d, J=2.2, 2H), 6.54 (d, J=12.2, 1H), 
6.73 (d, J=12.2, 1H), 7.25–7.29 (m, 1H), 7.53–7.56 (m, 2H), 8.20 (s, 1H). Anal. 
Calcd for C17H16N2O2: C, 72.84; H, 5.75; N, 9.99. Found: C, 72.66; H, 5.76; N, 
9.95. 
(Z)-5-[2-(3,5-Dimethoxyphenyl)-ethenyl]-1methylbenzoimidazole (30b). Eluent: 
Diethyl ether–light petroleum 3:7; Yield 28% 1H NMR (CDCl3, 400 MHz) δ: 3.06 
(br, 1H), 3.65 (s, 6H), 3,81 (s, 3H), 6.35 (t, J=2.2, 1H), 6.40 (d, J=2.2, 2H), 6.59 (d, 
J=12.2, 1H), 6.83 (d, J=12.2, 1H), 7.27–7.31 (m, 1H), 7.51–7.55 (m, 2H), 8.22 (s, 
1H). Anal. Calcd for C17H16N2O2: C, 72.84; H, 5.75; N, 9.99. Found: C, 72.66; H, 
5.76; N, 9.95. 
 
Synthesis of isocyanate intermediate (32). To a mixture of amino stilbene 27, free 
base (1.8 mmol, 519 mg) solubilized in dry dioxane (15 mL), trichloromethyl 
chloroformate (0.84 mmol, 105µl), was added in one portion. The mixture was 
heated at 60°C for 2 h. After cooling down to room temperature the mixture was 
concentrated in vacuo and the crude residue was used for the next reaction without 
any purification. 
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(Z)-{5-[2-(3,5-Dimethoxyphenyl)-ethenyl]-2-methoxyphenyl}carbamic acid 2-
[2-(2-hydroxyethoxy)ethoxy]ethyl ester (PD5). To solution of triethylene glycol 
(TEG, 5 mmol, 0.67 ml) in dry dioxane (5 ml) the crude isocyanate 32 (0.49 mmol, 
160 mg) dissolved in dry dioxane (3 ml) was added in one portion. The reaction 
mixture was heated at 60°C for 48 h. After cooling down to room temperature, the 
mixture was concentrated in vacuo and the residue was purified by flash 
chromatography (3% methanol/ dichloromethane) on silica gel to afford the 
expected compound 8c. Oil, 200 mg; Yield 89%. 1H NMR (CDCl3, 400 MHz) δ: 
2.55 br, (1H), 3.61–3.76 (m, 16H), 3.81 (s, 3H), 4.29–4.34 (m, 2H), 6.30 (t, J=2.2, 
1H), 6.43 (d, J=12.0, 1H), 6.44 (d, J=2.2, 2H), 6.53 (d, J=12.0, 1H), 6.56 (d, J=8.4, 
1H), 6.92 (d, J=2.2, J=8.4, 1H), 7.93 (s, 1H), 8.02 (d, J=2.2, 1H). 13C NMR (CDCl3, 
400 MHz) δ:  55.3, 55.8, 61.8, 64.0, 69.5, 70.4, 70.6, 72.5, 99.8, 106.7, 109.7, 119.3, 
123.5, 127.3, 129.1, 130.1, 130.5, 139.4, 146.9, 153.2, 160.5. Anal. Calcd for 
C24H31NO8: C, 62.46; H, 6.77; N, 3.04. Found: C, 62.67; H, 6.79; N, 3.05. 
 
(Z)-1-{5-[2-(3,5-Dimethoxyphenyl)-ethenyl]-2-methoxyphenyl}-3-(2-morpholin 
4-yl-ethyl)-urea hydrochloride salt (PD6). To a solution of crude isocyanate 32 
(0.61 mmol, 200 mg) solubilised in dry dioxane (5 ml) 4-(2-aminoethyl) 
morpholine, (0.67 mmol, 88 mg) was added portionwise. The mixture was heated at 
60°C for 12 h. After cooling down to room temperature, the mixture was 
concentrated in vacuo and the crude residue was purified by flash chromatography 
(3% methanol/dichloromethane) on silica gel to afford 105 mg of the expected title 
morpholine derivative. The compound (0.5 mmol, 220 mg) was dissolved in ethyl 
acetate and a slight excess of 0.1 N hydrochloride solution was added at 0°C. The 
mixture was stirred about 30 min at room temperature. The solvent was evaporated 
in vacuo and the solid residue was washed twice with few ml of diethyl ether to give 
205 mg of title compound. Yield 70%. 1H NMR (CDCl3, 400 MHz) δ: 2.83–3.02 
(m, 2H), 3.15–3.30 (m, 2H), 3.46–3.66 (m, 8H), 3.67–3.78 (m, 2H), 3.81 (s, 3H), 
3.94–4.10 (m, 2H), 4.16–4.35 (m, 2H), 6.26 (t, J=2.4, 1H), 6.40 (d, J=12.6, 1H), 
6.42 (d, J=2.4, 2H), 6.52 (d, J=12.6, 1H), 6.63, 6.67 (m, 1H), 6.90 (dd, J=1.6, J=8.4, 
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1H), 7.39 (s, 1H), 8.0 (s, 1H). 13C NMR (CDCl3, 400 MHz) δ: 36.0, 53.8, 55.8, 56.5, 
60.2, 65.2, 100.8, 108.0, 111.4, 121.8, 125.1, 129.3, 130.4, 131.4, 131.7, 140.8, 
149.5, 159.4, 162.2. Anal. Calcd for C24H32ClN3O5: C, 60.31; H, 6.75; Cl, 7.42; N, 
8.79. Found: C, 60.18; H, 6.74; Cl, 7.40; N, 5.80. 
 
(Z)-{5-[2-(3,5-Dimethoxyphenyl)-ethenyl]-2-methoxyphenyl} carbamic acid 2-
morpholin-4-yl-ethyl ester, hydrochloride (PD7). To a solution of the crude 
isocyanate 32 (0.59 mmol, 180 mg) solubilised in dry dioxane (5 mL) the 4-(2-
hydroxylethyl)morpholine, (0.6 mmol, 74 µl) was added portionwise. The mixture 
was heated at 60°C for 12 h. After cooling down to room temperature the mixture 
was concentrated in vacuo and the crude residue was purified by flash 
chromatography (3% methanol/dichloromethane) on silica gel to afford 117 mg of 
the expected desired carbamate. The compound (0.5 mmol, 220 mg) was dissolved 
in tetrahydrofuran (THF, 7 ml) and mixed with 0.1 N hydrochloride acid solution (a 
slight excess) in THF (5 ml). The hydrochloride salt PD7 separates as a colorless 
solid that was filtrated and washed with 10 ml of THF to give 212 mg. Yield 75%. 
Mp 152–154°C. 1H NMR (CDCl3, 400 MHz) δ: 2.86–3.0 (m, 2H), 3.28–3.35 (m, 
2H), 3.49 3.55 (m, 2H), 3.67 (s, 6H), 3.82 (s, 3H), 3.92–4.06 (m, 2H), 4.28–4.44 (m, 
2H), 4.67–4.72 (m, 2H), 6.30 (t, J=2.2, 1H), 6.41 (d, J=2.2, 2H), 6.45 (d, J=12.0, 
1H), 6.54 (d, J=12.0, 1H), 6.70 (d, J=8.2, 1H), 6.97 (dd, J=2.2, J=8.2, 1H), 7.42 (s, 
1H), 7.92 (s, 1H), 13.45 (br, 1H). 13C NMR (CDCl3, 400 MHz) δ: 52.5, 55.3, 55.8, 
56.6, 58.5, 63.6, 99.7, 106.7, 109.9, 119.4, 124.3, 126.5, 129.3, 129.9, 130.2, 139.3, 
147.2, 152.1, 160.5. Anal. Calcd for C24H31ClN2O6: C, 60.18; H, 6.52; Cl, 7.40; N, 
5.85. Found: C, 60.05; H, 6.53; Cl, 7.42; N, 5.84. 
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2.6. Terphenyl Derivatives 
 
The research goal in the field of stilbene derivatives is to develop novel, potent and 
low toxic pro-apoptotic agents. The group where I stay during my PhD thesis has a 
strong experience in this field, and another approach to modify the stilbene motif to 
improve its potency is act on ethylenic-bridge. The substitution of this double bond 
with another phenyl moiety was saw to be often advantageous. Terphenyl structure 
is reported as part also of other interesting analogues of natural compounds active on 
cell cycle, such as resveratrol. Hence, we discovered that some terphenyl derivatives 
(Fig.1) led to a growth rate enhancement in the tested cell population with respect to 
control. Confirmation of such protective behaviour was found by testing these 
compounds on HL60 cells cultured with serum-free medium and, moreover, on 
neuronal cells exposed to proapoptotic agents.32 
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 Fig.1. Known terphenyl derivatives endowed with cell growth-supporting activity. 
 
To continue the search for structural modifications needed for new drugs active on 
cell cycle we therefore planned further modifications on the terphenyl backbone, 
present in the most active derivatives found in previous studies. 
Starting from the previous active terphenyl derivatives (Fig.1) we decided three 
synthetic strategies: the substitution of trimethoxy-moiety with an 3-adamantyl-4-
hydroxyphenyl group; the change of central phenyl ring with another heteroaromatic 
ring; the substitution of the carboxylic group with an amino one. 
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2.6.1. Chemistry 
 
 For the synthesis of these new terphenyl derivatives we decided to substitute the 
trimethoxy-moiety with an adamantanyl one, a substitution set recurring in known 
compound CD4371433 and in more recent derivatives34 that regulate the mechanisms 
promoting differentiation and/or apoptosis in several cancer cell lines. Moreover, we 
previously found that derivatives bearing such substitution are endowed with either 
agonistic or antagonistic behavior toward apoptotic induction.35 
From a synthetic point of view, the preparation of these compounds is based on two 
Suzuki reactions as shown in Scheme 1. 
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Scheme 1. Regents and conditions: (i) Pd(Ph3P)4, aq. Na2CO3, toluene/EtOH, (ii) aq. KMnO4, 
(iii) H2SO4 conc., CH2Cl2, (iv) Benzyl bromide, K2CO3, CH3CN, (v) BuLi, B(OiPr)3, THF, (vi) 
Pd(Ph3P)4, aq. Na2CO3, CH3CN, (vii) H2, 5% Pd/C, EtOH. 
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The desired 2′-, 3′-, or 4′-bromobiphenyl carboxylic acids were prepare with a first 
Suzuki reaction between boronic acid 4 and 2′-, 3′-, or 4′-bromo-iodobenzene. After 
oxidation by potassium permanganate, a second Suzuki coupling with the 
adamantanyl boronic acid 12 occurs, to give, previous deprotection, the desired 
triphenyl derivatives in good yields. Compound 12 was prepare starting to p-bromo-
phenol, which after a Friedel-Craft alkylation with 1-adamantan-ol, and benzyl 
protection, reacted with triisopropyl borane in presence of butyllhythium at -78°C to 
give the appropriate boronic acid.  
With the aim to substitute the central phenyl ring with an heteroatomic one, we 
synthesized the isoxazolines and isoxazoles as described in Scheme 2. 
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Scheme 2. Synthesis of isoxazolines. Reagents and conditions: (i) MeI, KOH, DMSO, (ii) 
Ac2O, reflux, (iii) NH2OHxHCl, NaHCO3, MeOH, (iv) MeP(Ph)3Br, NaH, THF, (v) NCS, 
CHCl3, TEA, (vi) LiOH, H2O/MeOH. 
. 
Starting from the aldehyde 16 and after classical methylation or acetylation, 17a and 
b reacted with hydroxylamine hydrochloride to give oximes 18a,b, or with methyl-
triphenylphosphonium bromide in a Wittig reaction to give alkenes compounds 
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19a,b in good yields. Then, the nitrile oxides generated from oximes 18a,b 
following Torssell’s procedure36 underwent a [3 + 2] regioselective cycloaddition 
with alkenes 20a,b to produce isoxazolines 22a-c in good yields. In the same 
manner, isoxazolines 24a-c were obtained from nitrile oxides generated from oximes 
21a,b, and alkenes 19a,b. Alkaline hydrolysis of compounds 22c and 24c  gave the 
corresponding carboxylic acids 23 and 25. 
To prepare the isoxalozes we oxidize the isoxazoline ring using N-
bromosuccinimide-triethylamine in methylene chloride (Scheme 3). 
 
 
RO
ON
R1 RO
ON
R1
26a R=CH3, R1=COOCH3
26c R=Acetyl, R1=COOCH3
27 R=CH3, R1=COOH
28 R=H, R1=COOH
26b R=Acetyl, R1=NO2
29 R=H, R1=NO2
30 R=H, R1=NH2
i
ii
ii
iii
RO
NO
R1
RO
NO
R1
31a R=CH3, R1=COOCH3
31c R=Acetyl, R1=COOCH3
32 R=CH3, R1=COOH
33 R=H, R1=COOH
31b R=Acetyl, R1=NO2
34 R=H, R1=NO2
35 R=H, R1=NH2
ii
iii
ii
i
22a-c
24a-c
 
Scheme 3. Synthesis of isoxazoles. Reagents and conditions: (i) NBS, CCl4, reflux, (ii) LiOH, 
H2O/MeOH, (iii) Zn, AcOH. 
 
 
Thus, isoxazoles 27-29, 32-34 were obtained by alkaline hydrolysis of the respective 
methyl esters; and, in order to prepare amino derivatives instead of carboxylic acids, 
compounds 30 and 35 were synthesized by reduction of nitro group of 29 and 30. 
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2.6.2. Biological results 
 
To valuated the biological activity of this new set of terphenyl compunds, we tested 
their different concentrations on HL60 cells growth (Fig.2) 
 
 
Fig.2 Effects of novel terphenyl, diarylisoxazole, and diarylisoxazoline derivatives on HL60 
cell growth. 
 
 
All compounds caused a cell growth inhibition when used at concentrations higher 
than 10 µM. Compounds 15 and 33 were the most active antiproliferative agents, 
showing an IC50 of 8 and 3 µM, respectively.  
Surprisingly, compounds 29, 34, and 25 caused an increase of cell growth when 
used at low (<10 µM) concentration. In particular, we observed that compound 29 
was at the concentration of 2.5 µM was the most active in improving cell growth; it 
was able to increase the percentage of cells in S and G2-M phases of the cell cycle 
with a decrease in the percentage of cells in G0-G1 phase (Fig.3). This observation 
suggests that compound 29 might stimulate cell growth by promoting the G1-S 
transition. 
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Fig.3 Cell cycle distribution of HL60 cells (a) and HL60 cells exposed 24 h to 2.5 µM 
compound 29 (b). 
 
 
Thus, excited by this unexpected finding, we conducted further test to prove our 
hypothesis. Hence, we evaluated whether compounds 29, 34, and 25 were able to 
support growth and to avoid death of cells cultured in a serum-free medium. As is 
well-known, serum is an essential constituent of a cell culture medium to support the 
in vitro growth of continuous cell lines. Accordingly, HL60 cells were washed twice 
with PBS and suspended in a serum-free medium constituted by only RPMI 1640. 
After 72 h, cells were harvested and the number of living cells was determined. As 
reported in Fig.4, cells cultured 72 h in serum-free medium showed a cell growth 
inhibition of 70% compared to cells growing in a complete medium.  
 
   
 
Fig. 4 (a) Effects of compounds 34, 29, and 25 on cell growth of HL60 cells growing in serum-
free medium (-FCS). (b) Effects of compound 29 on apoptosis induced by serum deprivation. 
Bars represent ± SE of three independent experiments. 
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Compound 29 was able to support growth of cells cultured in serum-free medium 
especially when used at the concentration of 5 µM (Figure 4a). Compound 34 was 
less effective than 29, although it was able to support in part cell growth when used 
at 1 and 2.5 µM concentrations. In contrast, compound 25 (1 µM) did not show any 
cell growth stimulating activity in serum free medium and, at 2.5 and 5 µM 
concentrations, it caused instead a potent cell growth inhibition. Moreover, 
compound 29 was also able to inhibit apoptosis of cells cultured in serum-free 
medium. As shown in Figure 4b, serum deprivation induced apoptosis in about 40% 
of HL60 control cells (evaluation after 72 h of culture), whereas addition with 2.5 or 
5 µM of 29, reduced the percentage of apoptosis to only 10%. Compounds 2 and 3 
were able to decrease the percentage of apoptosis of HL60 from about 40% to 18% 
and 17%,9 resulting in being less active than 29 as antiapoptotic agent. 
Thus, also these new data demonstrated that terphenyl derivative 29 acts as a 
proliferative stimulating and antiapoptotic agent. To better verify this latter property, 
we tested the ability of 29 to inhibit the apoptotic activity of daunorubicin, a 
chemotherapic agent that potently induces apoptosis in HL60 cells. After 48 h of 
exposure to increasing concentrations of daunorubicin alone or in combination with 
2.5 µM of 30, HL60 cells were harvested and the percentage of apoptosis was 
determined. As reported in Figure 5, 29 was able to halve the percentage of 
apoptosis induced by daunorubicin.  
 
 
Fig. 5. Percentage of apoptosis of HL60 cells after 48 h exposure to different concentrations of 
daunorubicin in combination or not with compound 29. Bars represent ± SE of three 
independent experiments. 
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The daunorubicin is an anthracycline (daunorubicin, idarubicin, epirubicin, and 
doxorubicin), widely used cytotoxic drugs in the treatment of haematological 
malignancies and solid tumors. These agents are especially prone to causing severe 
tissue damage on extravasation by inducing apoptosis in skin cells. Accidental 
extravasation has been estimated to occur in 0.5-6% of all patients receiving 
chemotherapy.21–23 The local toxicity is characterized by immediate pain, erythema, 
and swelling at the extravasation site. The ulceration may not appear for several 
days or even weeks and may continue to worsen for months, probably because of 
drug diffusion into adjacent tissue. Indeed, it has been demonstrated that 
doxorubicin can persist in the tissue for at least a month. Whereas small 
ulcerations may heal, large ulcerations require surgical excision. The ability of 
29 to inhibit apoptosis induced by daunorubicin suggests that a topical use of 
this compound could be useful for the treatment of tissue damage caused by 
extravasation of anthracyclines.  
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2.6.3. Conclusions 
 
In this part of research, we studied a further modification on stilbene motif to 
synthesize novel compounds with pro-apoptotic activity. In previous work of 
my research group was reported the activity of some terphenyl derivatives, where 
the double bond of stilbene was replace by another phenyl ring. Thus, the goal 
was prepare others compounds with further substitutions on terphenyl core.  
Hence, we achieve three different kind of structural modifications: the 
replacement of trimethoxyl-moiety with an adamantnyl-group; the central 
phenyl ring with an heteroaromatic other; and the carboxylic acid with an amino 
group. 
Thus, we tested these new compounds on HL60 cells to evaluate their apoptotic 
activity. Surprisingly, these structural modifications lead to derivatives with 
opposite activity toward cell growth. In fact, we observed that some derivatives 
act as inductors of growth cells and as antiapoptotic agents at low 
concentrations. Among compounds with carboxylic acid function at ring C, only 
isoxazolinic 25 has shown a small growth enhancing property, but not in serum-
free conditions. None of the amino compounds were found of interest but, 
unexpectedly, their nitro precursors 29 and 34 showed interesting cell growth 
promoting and antiapoptotic activities. In particular, compound 29 was able to 
support effectively the cell growth of HL60 cultured in serum-free medium, 
preventing apoptosis induced by serum deprivation. The apoptosis inhibitory 
effect of 29 was still observed when cells were exposed to the potent apoptotic 
inducing factor daunorubicin. 
This activity is very interesting because high apoptosis level causes different 
disease, especially in central nervous system. In fact inappropriate apoptosis in 
the brain leads to permanent neurological deficits. Disregulated apoptosis has 
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been implicated in several neurodegenerative disorders. Moreover, this is the 
cause of local toxicity of some antineoplastic agents, as anthracyclines, which 
can lead to several skin maligniances.  
In conclusion, our data indicate that compound 29 is a potent cell growth agent 
endowed with antiapoptotic activity, and could be involved in therapy to inhibit 
undesired effects of a widely used traditional chemotherapy. Therefore, further 
studies on terphenyl derivatives could improve the research of cell growth 
inducing agents, in the field of neurological deficits and neurodegenerative 
disorders. 
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2.6.4. Experimental Section 
 
Chemistry 
Melting points were obtained with a Kofler apparatus and are uncorrected. 
Reaction courses and product mixtures were routinely monitored by thin-layer 
chromatography (TLC) on silica gel precoated F254 Merck plates. Nuclear 
magnetic resonance (1H and 13C NMR) spectra were determined in CDCl3 
solution, unless otherwise indicated, with a Bruker AC-200 spectrometer, and 
peak positions are given in parts per million downfield from tetramethylsilane 
as internal standard. All drying operations were performed over anhydrous 
sodium sulfate. Column chromatography (medium pressure) was carried out with 
60-200 mesh silica gel, using the flash technique. Microanalysis of all new final 
synthesized compounds agreed with calculated values within ± 0.4% of the 
theoretical. 
 
General Procedure for Biphenylcarbaldehyde Synthesis (6). To a solution of 
o-, m-, or p-iodobromobenzene (120 mg, 0.42 mmol) in 1 ml of toluene is added 
a catalytic amount (3-5% mol) of tetrakis-triphenylphosphine palladium and 0.3 
ml of aqueous 2 M Na2CO3. A solution of 4-formylbenzeneboronic acid (4, 100 
mg, 0.66 mmol) in 1 ml of ethanol is then added, and the mixture is heated to 
reflux for 3 h in an argon atmosphere. After cooling, the mixture is extracted 
three times with dichloromethane and the joined organic phases are washed with 
water and brine, dried, and evaporated under vacuum. The residue is purified by 
chromatography, giving the bromodiphenylaldehyde derivative. 
2’-Bromobiphenyl-4-carbaldehyde (6a).36 Oil. Yield 30%. 1H NMR (CDCl3, 200 
MHz) δ: 7.26-7.41 (m, 3H), 7.60 (d, J=8.1, 2H), 7.71 (d, J=8, 1H), 7.97 (d, 
J=8.3 2H), 10.09 (s, 1H). 
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3’-Bromobiphenyl-4-carbaldehyde (6b).37 Oil. Yield 50%. 1H NMR(CDCl3, 200 
MHz) δ: 7.37,( J=7.7, 1H), 7.57 (m, 2H), 7.72 (d, J=9.2, 2H), 7.77 (m, 1H), 
7.96 (d, J =9, 2H), 10.07 (s, 1H). 
4’-Bromobiphenyl-4-carbaldehyde (6c).38 Solid. Mp 135- 140°C. Yield 62%. 
1H NMR (CDCl3, 200 MHz) δ: 7.50 (d, J=8.8, 2H), 7.62 (d, J=8.8, 2H), 7.72 (d, 
J=8, 2H), 7.96 (d, J=8.6, 2H), 10.06 (s, 1H). 
 
General Procedure for Oxidation to Biphenylcarboxylic Acid (7a-c). To a 
gently boiling solution of bromobiphenylcarbaldehyde (6a-c, 100 mg) in 
sodium carbonate (5 mL) is added potassium permanganate (70 mg in 1 mL of 
water), and reflux is maintained for 3 h. After cooling, the solution is acidified 
with concentrated hydrochloric acid and extracted three or more times with 
diethyl ether. The residue is used in the next reaction with no further purification. 
2’-Bromobiphenyl-4-carboxylic Acid (7a).39 Yield 99%. Mp 237-241 °C. 1H 
NMR (DMSO-d6, 200 MHz): δ 7.40-7.70 (m, 5H), 8.00-8.10 (m, 3H). 
3’-Bromobiphenyl-4-carboxylic Acid (7b).39 Yield 99%. Mp 250-253 °C. 1H 
NMR (DMSO-d6, 200 MHz): δ 7.40-7.85 (m, 6H), 8.11 (d, J =8.4, 2H). 
4’-Bromobiphenyl-4-carboxylic Acid (7c).39 ,4 0 Yield 98%. Mp >300 °C. 1H 
NMR: (DMSO-d6, 200 MHz): δ  7.50 (d, J=8.8, 2H), 7.59-7.68 (m, 4H), 8.16 (d, 
J =8.6, 2H). 
 
General Procedure for Terphenyl Synthesis. To a solution of bromobiphenyl 
acid (7a-c, 1 eq) and 4-Benzyloxy-3-tricyclo[3.3.1.10,0]dec-1-yl-boronic acid 
(12, 1 eq) in 0.4 M aqueous sodium carbonate (5 ml) and acetonitrile (5 ml) is 
added a catalytic amount (5% mole) of tetrakis-triphenylphosphine palladium, 
and the mixture is heated to reflux under argon atmosphere for 3 h. The 
suspension is cooled, filtered, and washed with dichloromethane. The water 
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phase is then acidified and extracted with diethyl ether. Purification of the residue 
of ether extracts gave the O-protected terphenyl products. 
 
General Procedure for Removal of the Benzyl-Protection Group. To a 
solution of the appropriate benzyl protected derivative (0.11 mmol) in abs EtOH 
(15 mL) was added Pd/C 5% (catalytic amount). The reaction was stirred in 
hydrogen atmosphere for 15 h. The mixture was filtered over celite and the 
solution evaporated. The residue was chromatographed on silica gel (light 
petroleum-ethyl acetate). 
4-Hydroxy-3-tricyclo[3.3.1.10,0]dec-1-yl-[1,1 ;4 ,1  ]terphenyl-4  -
carboxylic Acid (13). Yield 40%; mp 300 °C (dec.). 1H NMR (DMSO-d6, 200 
MHz): δ 1.71 (s, 6H), 2.01 (s, 9H), 5.76 (s, 1H), 7.46-7.52 (m, 4H), 7.72-7.82 
(m, 5H), 8.01 (d, J=8.2, 2H), 12.96 (br, 1H). 13C NMR (DMSO-d6, 200 MHz): 
δ 28.1, 37.1, 43.1, 44.1, 121.0, 126.1, 127.5, 128.7, 130.5, 131.6, 134.3, 140.8, 
141.0, 142.4, 143.1, 162.4, 167.2.  
4-Hydroxy-3-tricyclo[3.3.1.10,0]dec-1-yl-[1,1 ;3 ,1  ]terphenyl-4  -
carboxylic acid (14). Yield 35%; mp 263-265 °C. 1H NMR (DMSO-d6, 200 
MHz): δ 1.80 (s, 6H), 2.11 (s, 3H), 2.19 (s, 6H), 5.12 (s, 1H), 6.76 (d, J=8.0 , 
1H), 7.34 (dd, J=8.0, J=1.8, 1H), 7.48-7.60 (m, 4H), 7.73-7.77 (m, 3H), 8.20 
(d, J=8.0, 2H), 12.47 (br, 1H). 13C NMR (DMSO-d6, 200 MHz): δ 28.1, 37.1 , 
43.1, 44.1, 120.4, 127.3, 129.8, 132.1, 135.5, 136.8, 139.1, 141.6, 142.5 , 
143.6, 162.4, 167.2. 
4-Hydroxy-3-tricyclo[3.3.1.10,0]dec-1-yl-[1,1 ;2 ,1  ]terphenyl-4  -
carboxylic Acid (15). Yield 47%; mp 179-181 °C. 1H NMR (CD3OD, 200 MHz) δ 
1.86 (s, 6H), 1.92 (s, 9H), 5.49 (s, 1H), 6.60 (d, J=8.1, 1H), 6.70 (d, J=2.1 , 
1H), 6.86 (dd, J=8.1, J =2.1, 1H), 7.09 (d, J =8.1, 2H), 7.35-7.40 (m, 4H), 7.86 
(d, J=8.1, 2H), 12.3 (br, 1H). 1H NMR (CD3OD, 200 MHz) δ 28.1, 37.1, 43.1 , 
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44.1, 121.5, 123.7, 125.1, 127.5, 130.9, 133.8, 136.7, 139.3, 139.6, 141.2 , 
141.5, 142.7, 161.7, 167.2.  
 
2- tricyclo[3.3.1.10,0]dec-1-yl -4-bromo-phenol (10). To a suspension of 4-
bromo-phenol 8 (0,011 mmol) and adamant-1-ol 9 in dichloromethane (15-20 
ml) were added dropwise H2SO4 conc  After complete dissolution, the reaction 
was poured into water, neutralized  with bicarbonate satured solution and 
extracted with dichloromethane. The organic layers were collected, dried on 
anhydrous sodium sulphate, filtered and evaporated in vacuo. The crude material 
was purified by chromatography (petroleum ether/ethyl ether) to give product 10 
(yield 65%). 1H NMR(CDCl3, 200 MHz) δ:  1.77 (s, 6H), 2.09 (s, 9H), 4.86 (s, 
1H), 6.56 (d, 1H, J=8.24), 7.13-7.17 (m, 1H), 7.26-7.30 (m, 1H). 
 
3-tricyclo[3.3.1.10,0]dec-1-yl-4-benzyloxyphenyl bromide (11). To a 
suspension of potassium carbonate in acetonitrile was added hydroxyl-derivative 
10 and the reaction was stirred at reflux for 4h. After cooling to room 
temperature, the solid was filtered off and the solvent concentrated in vacuo. The 
crude material was then crystallized by hexane giving the desired product 11. 
(yield 88%). 1H NMR(CDCl3, 200 MHz) δ: 1.75 (s, 6H), 2.05 (s, 9H), 4.93 (s , 
2H), 6.56 (d, 1H, J=8.23), 7.10-7.17 (m, 6H), 7.30-7.34 (m, 1H). 
 
3-tricyclo[3.3.1.10,0]dec-1-yl-4-benzyloxyphenylboronic Acid (12). To a 
solution of 3-tricyclo[3.3.1.10,0]dec-1-yl-4-benzyloxyphenyl bromide 11 (2.00 
g, 5.04 mmol) in THF (7 ml) at -78 °C (dry ice/acetone bath) under argon was 
added in one 
portion 1.6 M n-BuLi (7.56 mmol) in hexane (4.7 ml). The mixture was stirred at 
-78 °C for 15 min, (i-PrO)3B (3.5 ml, 15.1 mmol) was added, and the resulting 
solution was stirred at -78 °C for 20 min and then at room temperature overnight . 
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The mixture was quenched with 0.1 N HCl (30 ml) and extracted with EtOAc. The 
extracts were washed with brine and dried over anhydrous sodium sulphate. After 
filtration and evaporation of the solvent, the crude product was used without 
further purifications. 
 
4-Methoxy-3-tricyclo[3.3.1.10,0]dec-1-yl-benzaldehyde (17a). To a suspension 
of KOH pulverized (450 mg, 7.9 mmol) in DMSO (10 ml) that was stirred for 15 
min was added 16 (500 mg, 1.96 mmol) and then iodomethane (0.25 ml, 3.9 
mmol). After stirring for 2 h at room temperature, dichloromethane (30 ml) was 
added and the mixture was poured into ice-water and extracted three times with 
dichloromethane. The combined organic extracts were washed with water, brine,  
dried, and evaporated, and the residue was chromatographed on silica gel (light 
petroleum-ethyl acetate 9/1) to give compound 17a (oil, 380 mg, yield 73%). 1H 
NMR(CDCl3, 200 MHz) δ:  1.79 (s, 6H); 2.11 (s, 9H); 6.97 (d, J=8.4, 1H), 7.70-
7.79 (m, 2H,); 9.89 (s, 1H). 
 
Acetic Acid 4-Formyl-2-tricyclo[3.3.1.10,0]dec-1-yl-phenyl Ester (17b). A 
solution of 16 (4.3 g, 17 mmol) in acetic anhydride (20 ml) was refluxed for 1 h. 
After evaporation, diethyl ether (30 ml) was added to the residue and washed with 
5% NaHCO3 (15 ml), water, and brine, dried over Na2SO4, and evaporated. The 
residue was purified by chromatography to give compound 17b (oil, 4.28 g, yield 
85%). 1H NMR(CDCl3, 200 MHz) δ: 1.77 (s, 6H), 2.12 (s, 9H), 2.40 (s, 3H), 
7.17 (d, J=8.1, 1H) 7.75 (dd, J=8.1, J ) 1, 1H), 7.90 (d, 1H), 9.97 (s, 1H). 
 
General Procedure for Oximes. To a solution of hydroxylamine hydrochloride 
(250 mg, 3.7 mmol) dissolved in water (7 ml), NaHCO3 (470 mg, 5.6 mmol) was 
added portionwise at 0 °C, and the mixture stirred for 30 min at room temperature. 
The appropriate aldehyde (17a,b, 3.1 mmol), dissolved in methanol (5 ml), was 
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then added to the solution and stirring was continued for additional 6 h . 
Methanol was evaporated in vacuo and the residue extracted with diethyl ether. 
The organic extracts were washed with brine, dried, and evaporated under reduced 
pressure. The residue was chromatographed on silica gel (diethyl ether-light 
petroleum). 
4-Methoxy-3-tricyclo[3.3.1.10,0]dec-1-yl-benzaldehyde Oxime (18a). Yield 
75%; mp 158-160 °C. 1H NMR(CDCl3, 200 MHz) δ: 1.77 (s, 6H), 2.09 (s,9H), 
3.86 (s, 3H), 6.87 (d, J=8.3, 1H), 7.33-7.38 (m, 2H), 7.48 (s, 1H), 8.09 (s, 1H). 
Acetic Acid 4-(Hydroxyimino-methyl)-2-tricyclo[3.3.1.10,0]dec- 1-yl-phenyl 
Ester (18b). Yield 98%, oil. 1H NMR(CDCl3, 200 MHz) δ: 1.77 (s, 6H), 2.02 (s , 
9H), 2.37 (s, 3H), 7.02 (d, J=8.1, 1H), 7.42 (dd, J=8.1, 2, 1H), 7.58 (d, 1H), 
8.12 (s, 2H). 
4-(Hydroxyiminomethyl)benzoic Acid Methyl Ester (21a). Yield 80%; mp 
119-122 °C. 1H NMR(CDCl3, 200 MHz) δ: 3.9 (s, 3H); 7.27 (s, 1H); 7.69 (d, 
J=8.4, 2H); 8.06 (d, J ) 8.3, 2H); 8.17 (s, 1H). 
 
General Procedure for Olefins. NaH (1.2 eq), was added to a stirred suspension 
of methyltriphenylphosphonium bromide (1.07 g, 3 mmol) in dry THF (15 ml) 
containing the appropriate aldehyde (17a,b, 3 mmol). After stirring for 5 h at 
room temperature, diethyl ether (30 ml) was added and the mixture was poured 
into ice-water and extracted with Et2O. The combined organic extracts were dried 
and evaporated, and the residue was chromatographed on silica gel (diethyl ether-
light petroleum). 
1-(2-Methoxy-5-vinyl-phenyl)-tricyclo[3.3.1.10,0]decane (19a). Yield 65%; oil . 
1H NMR(CDCl3, 200 MHz) δ: 1.78 (s, 6H), 2.11 (s, 9H), 3.83 (s, 3H), 5.12 (d, 
J=11.1, 1H), 5.61 (d, J=17.6, 1H), 6.68 (dd, J=17.6, J=11.1, 1H), 6.84 (d, 
J=8.4, 1H), 7.22-7.30 (m, 2H). 
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Acetic Acid 2-Tricyclo[3.3.1.10,0]dec-1-yl-4-vinyl-phenyl Ester (19b). Yield 
79%; oil. 1H NMR(CDCl3, 200 MHz) δ: 1.79 (s, 6H), 2.03 (s, 9H), 2.36 (s, 3H), 
5.23 (dd, J=11.1, J=0.6, 1H), 5.70 (dd, J=17.0, J=0.6, 1H), 6.71 (dd, J=17.1 , 
J=11.1, 1H), 6.96 (d, J=8.2, 1H), 7.29 (dd, J=8.2, J=2.1, 1H), 7.31 (d, J=2.1 , 
1H). 
4-Vinylbenzoic Acid Methyl Ester (20a). Yield 60%; oil. IR (neat) 1724 , 
1608, 1436, 1278, 1107, 782. 1H NMR(CDCl3, 200 MHz) δ: 3.91 (s, 3H), 5.38 
(d, J=10, 1H), 5.96 (d, J=17.6, 1H), 6.75 (dd, J=17.6, J=10, 1H), 7.46 (d, J=8, 
2H), 7.99 (d, J=8, 2H). 
 
General Procedure for Isoxazolines. A mixture of N-chlorosuccinimide (174 mg, 
1.3 mmol), pyridine (2 drops) and oxime (1.3 mmol) in anhydrous CHCl3 (15 ml) 
was stirred for 1 h at 50-60°C. Olefin (1.4 mmol) was then added followed by 
triethylamine (0.27 ml, 1.95 mmol) in CHCl3 (5 ml). After stirring at 25 °C for 20 
min, water was added and the organic phase was washed with 2.5% HCl and water, 
then dried and evaporated under reduced pressure. The residue was 
chromatographed on silica gel (ethyl acetate-light petroleum). 
4-[3-(4-Methoxy-3-tricyclo[3.3.1.10,0]dec-1-yl-phenyl)-4,5-dihydro-isoxazol-5-
yl]-benzoic Acid Methyl Ester (22a). Yield 80%. 1H NMR(CDCl3, 200 MHz) δ:  
1.76 (s, 6H), 2.09 (s, 9H), 3.30 (dd, J=16.1, J =7.9, 1H), 3.76-3.93 (m, 7H), 5.75 
(dd, J=11.2, J=7.9, 1H), 6.87 (d, J=8.4, 1H), 7.42-7.49 (m, 3H), 7.62 (s, 1H), 7.65 
(d, J=6.6, 2H), 8.04 (dd, J=8.2, J=1.8, 2H). 
Acetic Acid 4-[5-(4-Nitro-phenyl)-4,5-dihydro-isoxazol-3-yl]-2-
tricyclo[3.3.1.10,0]dec-1-yl-phenyl Ester (22b). Yield 42%. 1H NMR(CDCl3, 200 
MHz) δ: 1.78 (s, 6H), 2.01 (s, 6H), 2.09 (s, 3H), 2.37 (s, 3H), 3.29 (dd, J=16.4, 
J=7.2, 1H), 3.88 (dd, J=16.8, J=11.2, 1H), 5.83 (dd, J=10.8, J=7.2, 1H), 7.04 (d, 
J=8.4, 1H), 7.46 (dd, J=8.4, J=2.0, 1H), 7.55-7.58 (m, 2H), 7.74 (d, J=2.0, 2H), 
8.22-8.25 (m, 2H). 
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4-[3-(4-Acetoxy-3-tricyclo[3.3.1.10,0]dec-1-yl-phenyl)-4,5-dihydroisoxazol-5-yl]-
benzoic Acid Methyl Ester (22c). Yield 82%. 1H NMR(CDCl3, 200 MHz) δ: 1.77 
(s, 6H), 2.02 (s, 9H), 2.37 (s, 3H), 3.30 (dd, J=16.3, 1H), 3.83 (dd, J=16.5, J=11, 
1H), 3.92 (s, 3H), 5.79 (dd, J=11.1, J=7.6, 1H), 7.04 (d, J=8.3, 1H), 7.43-7.50 (m, 
3H), 7.55 (d, J=2, 1H), 8.05 (d, J=8.2, 2H). 
4-[5-(4-Methoxy-3-tricyclo[3.3.1.10,0]dec-1-yl-phenyl)-4,5-dihydro-isoxazol-3-
yl]-benzoic Acid Methyl Ester (24a). Yield 53%. 1H NMR(CDCl3, 200 MHz) δ: 
1.76 (s, 6H), 2.07 (s, 9H), 3.36 (dd, J=16.4, J=8.6, 1H), 3.65-3.83 (m, 4 H), 3.93 (s, 
3H), 5.72 (dd, J=11,2, J=8.6, 1H), 6.86 (d, J=8.8, 1H), 7.19-7.24 (m, 2H), 7.77 (d, 
J=8.1, 2H), 8.07 (d, J=8.2, 2H). 
Acetic Acid 4-[3-(4-Nitro-phenyl)-4,5-dihydro-isoxazol-5-yl]-2-
tricyclo[3.3.1.10,0]dec-1-yl-phenyl Ester (24b). Yield 45%. 1H NMR(CDCl3, 200 
MHz) δ: 1.76 (s, 6H), 2.0 (s, 6H), 2.08 (s, 3H), 2.35 (s, 3H), 3.44 (dd, J=17.0, J=8.0, 
1H), 3.78 (dd, J=17.0, J=11.0, 1H), 5.80 (dd, J=11.0, J=8.0, 1H), 7.0 (d, J=8.4, 
1H), 7.22 (dd, J=8.2, J=1.1, 1H), 7.85 (d, J=9.0, 2H), 8.27 (d, J=9.0, 2H). 
4-[5-(4-Acetoxy-3-tricyclo[3.3.1.10,0]dec-1-yl-phenyl)-4,5-dihydroisoxazol- 
3-yl]-benzoic Acid Methyl Ester (24c). Yield 44%. 1H NMR(CDCl3, 200 MHz) δ: 
1.76 (s, 6H), 2.01 (s, 9H), 2.35 (s, 3H), 3.37 (dd, J=16.7, J=8.6, 1H), 3.76 (dd, 
J=16.7, J=11.1, 1H), 3.93 (s, 3H), 5.76 (dd, J=11.2, J=8.6, 1H), 7.01 (d, J=8.2, 
1H), 7.24 (dd, J=8.2, J=2.1, 1H), 7.36 (d, J=2.1, 1H), 7.65 (d, J=6.6, 2H), 8.07 (d, 
J=6.7, 2H). 
 
General Procedure for Isoxazoles. To a solution of the isoxazoline (0.25 mmol) in 
carbon tetrachloride (10 ml), N-bromosuccinimide (66 mg, 0.37 mmol) was added 
and the mixture was gently refluxed for 3 h. Hydrogen bromide was slowly 
liberated. The cooled solution was filtered from the precipitated succinimide, 
washed with 5% aqueous sodium hydroxide and then with water until the organic 
phase became clear. The organic layer was dried and the solvent removed in vacuo. 
The residue was chromatographed on silica gel (ethyl acetate-light petroleum). 
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4-[3-(4-Methoxy-3-tricyclo[3.3.1.10,0]dec-1-yl-phenyl)-isoxazol-5-yl]-benzoic 
Acid Methyl Ester (26a). Yield 81%. 1H NMR(CDCl3, 200 MHz) δ: 1.80 (s, 6H), 
2.15 (s, 9H), 3.90 (s, 3H), 3.96 (s, 3H), 6.90 (s, 1H), 6.97 (d, J=8.2, 1H), 7.66-7.75 
(m, 2H), 7.92 (d, J =8.4, 2H) 8.16 (d, J =8.4, 2H). 
Acetic Acid 4-[5-(4-Nitro-phenyl)-isoxazol-3-yl]-2-tricyclo-[3.3.1.10,0]dec-1-yl-
phenyl Ester (26b). Yield 54%. 1H NMR(CDCl3, 200 MHz) δ: 1.72 (s, 6H), 2.02 (s, 
9H), 2.33 (s, 3H), 6.92 (s, 1H), 7.07 (d, J=8.4, 1H), 7.62 (dd, J=8.4, J=2.2, 1H), 
7.82 (d, J=2.2, 1H), 7.93-7.97 (m, 2H), 8.28-8.33 (m, 2H). 
4-[3-(4-Acetoxy-3-tricyclo[3.3.1.10,0]dec-1-yl-phenyl)-isoxazol-5-yl]-benzoic 
Acid Methyl Ester (26c). Yield 81%. 1H NMR(CDCl3, 200 MHz) δ: 1.80 (s, 6H), 
2.15 (s, 9H), 3.90 (s, 3H), 3.96 (s, 3H), 6.90 (s, 1H), 6.97 (d, J=8.2, 1H), 7.66-7.75 
(m, 2H), 7.92 (d, J=8.4, 2H) 8.16 (d, J=8.4, 2H). 
4-[5-(4-Methoxy-3-tricyclo[3.3.1.10,0]dec-1-yl-phenyl)-isoxazol-3-yl]-benzoic 
Acid Methyl Ester (31a). Yield 62%. 1H NMR(CDCl3, 200 MHz) δ: 1.80 (s, 6H), 
2.14 (s, 9H), 3.89 (s, 3H), 3.95 (s, 3H), 6.75 (s, 1H), 6.96 (d, J=8.4, 1H), 7.65-7.70 
(m, 2H), 7.95 (d, J=8.4 Hz, 2H), 8.15 (d, J=8.4, 2H). 
Acetic Acid 4-[3-(4-Nitro-phenyl)-isoxazol-5-yl]-2-tricyclo-[3.3.1.10,0]dec-1-yl-
phenyl Ester (31b). Yield 81%. 1H NMR(CDCl3, 200 MHz) δ: 1.81 (s, 6H), 2.07 (s, 
6H), 2.14 (s, 3H), 2.40 (s, 3H), 6.86 (s, 1H), 7.14 (dd, J=8.0, J=2.0, 1H), 7.84 (d, 
J=2.0, 1H), 8.05-8.07 (m, 2H), 8.34-8.37 (m, 2H). 
4-[5-(4-Acetoxy-3-tricyclo[3.3.1.10,0]dec-1-yl-phenyl)-isoxazol-3-yl]-benzoic 
Acid Methyl Ester (31c). Yield 65%. 1H NMR(CDCl3, 200 MHz) δ: 1.61 (s, 6H), 
2.08 (s, 9H), 2.40 (s, 3H), 3.96 (s, 3H), 6.84 (s, 1H), 7.13 (d, J =8.4, 1H), 7.69 (dd, 
J=8.4, J=2.1, 1H), 7.84 (d, J=2.1, 1H), 7.95 (d, J=8.3, 2H), 8.15 (d, J=8.3, 2H). 
 
General Procedure for Ester Hydrolysis. A mixture of ester (1 mmol), methanol 
(10 ml), water (6-7 ml), and lithium hydroxide (40 mg, 1.5 mmol or double amount 
for acetyl derivatives) was allowed to stand at 50-60°C for 24 h. The solution was 
concentrated in vacuo to remove methanol, and the remaining aqueous solution was 
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extracted with diethyl ether to separate trace amounts of unreacted ester. The 
aqueous solution was acidified with 1 M hydrochloric acid and extracted with three 
portions of ethyl acetate. The combined organic extracts were washed with saturated 
aqueous sodium chloride and dried. Removal of the solvent under reduced pressure 
afforded a residue, which was chromatographed on silica gel (eluent: ethyl acetate-
light petroleum). 
4-[3-(4-Hydroxy-3-tricyclo[3.3.1.10,0]dec-1-yl-phenyl)-4,5-dihydro-isoxazol-5-
yl]-benzoic Acid (23). Yield 90%; mp 251-253 °C (dec). 1H NMR(DMSO, 200 
MHz) δ: 1.72 (s, 6H), 2.06 (s, 9H), 3.27-3.39 (m, 1H), 3.86 (dd, J=17.1, J=11.1, 
1H), 5.75 (dd, J=10.7, J=7.4, 1H), 6.82 (d, J=8.4, 1H), 7.34 (d, J=8.4, 1H), 7.44-
7.51 (m, 3H), 7.95 (d, J=8.0, 2H), 9.86 (s, 1H), 12.98 (br, 1H). 13C NMR(DMSO, 
200 MHz) δ: 28.1, 37.1, 43.1, 44.1, 45.2, 81.1, 116.6, 128.7, 129.1, 129.6, 131.1, 
131.8, 132.7, 137.1, 158.1, 162.1, 167.2.  
4-[5-(4-Hydroxy-3-tricyclo[3.3.1.10,0]dec-1-yl-phenyl)-4,5-dihydro-isoxazol-3-
yl]-benzoic Acid (25). Yield 94%; mp 240-242 °C (dec). 1H NMR (DMSO-d6) δ 
1.71 (s, 6H), 2.05 (s, 9H), 3.38-3.46 (m, 1H), 3.79 (dd, J=16.4, J=11.2, 1H), 5.63 
(dd, J=11.2, J=8.3, 1H), 6.77 (d, J=8.1, 1H), 7.03-7.10 (m, 2H), 7.82 (d, J=8.3, 2H), 
8.0 (d, J=8.3, 2H), 9.43 (s, 1H), 12.90 (br, 1H). 13C NMR(DMSO-d6, 200 MHz) δ: 
28.1, 37.1, 43.2, 44.1, 45.2, 82.7, 118.8, 122.1, 126.1, 127.6, 129.6, 130.2, 133.6, 
134.3, 157.0, 158.9, 167.2.  
4-[3-(4-Methoxy-3-tricyclo[3.3.1.10,0]dec-1-yl-phenyl)-isoxazol-5-yl]-benzoic 
Acid (27). Yield 98%; mp 230 °C (dec). 1H NMR(DMSO-d6, 200 MHz) δ: 1.75 (s, 
6H), 2.09 (s, 9H), 3.87 (s, 3H), 7.14 (d, J=8.4, 1H), 7.70-7.77 (m, 3H), 8.02-8.09 
(m, 4H), 13.15 (br, 1H). 13C NMR(DMSO-d6, 200 MHz) δ: 28.1, 37.1, 43.1, 43.8, 
55.1, 95.1, 115.8, 126.3, 129.8, 130.5, 132.3, 132.7, 133.9, 158.5, 160.7, 163.5, 
167.2.  
4-[5-(4-Methoxy-3-tricyclo[3.3.1.10,0]dec-1-yl-phenyl)-isoxazol-3-yl]-benzoic 
Acid (32). Yield 95%; mp 230 °C (dec). 1H NMR(DMSO-d6, 200 MHz) δ: 1.76 (s, 
6H), 2.09 (s, 9H), 3.88 (s, 3H), 7.16 (d, J=8.8, 1H), 7.62 (s, 1H), 7.68 (d, J=1.8, 
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1H), 7.76 (d, J=8.8, J=1.8, 1H), 8.03-8.10 (m, 4H), 13.15 (br, 1H). 13C 
NMR(DMSO-d6, 200 MHz) δ: 28.1, 35.7, 37.1, 43.1, 55.1, 95.1, 116.4, 128.9, 129.0, 
129.5, 130.2, 129., 133.3, 133.9, 157.5, 160.7, 164.9, 167.2.  
4-[3-(4-Hydroxy-3-tricyclo[3.3.1.10,0]dec-1-yl-phenyl)-isoxazol-5-yl]-benzoic 
Acid (28). Yield 95%; mp 251-253 °C (dec). 1H NMR(DMSO-d6, 200 MHz) δ: 1.75 
(s, 6H), 2.10 (s, 9H), 6.91 (d, J=8.1, 1H), 7.57-7.70 (m, 3H), 8.01-8.12 (m, 4H), 
9.88 (s, 1H), 13.25 (br, 1H). 13C NMR(DMSO-d6, 200 MHz) δ: 28.1, 37.1, 43.1, 
44.1, 95.1, 117.1, 128.4, 129.8, 130.5, 132.3, 134.1, 135.0, 158.5, 162.4, 163.5, 
167.2.  
4-[5-(4-Hydroxy-3-tricyclo[3.3.1.10,0]dec-1-yl-phenyl)-isoxazol-3-yl]-benzoic 
Acid (33). Yield 95%; mp 241 °C (dec). 1H NMR(DMSO-d6, 200 MHz) δ: 1.75 (s, 
6H), 2.06 (s, 9H), 6.93 (d, J=8.1, 1H), 7.51 (s, 1H), 7.59 (d, J=8.4, 2H), 8.04-8.09 
(m, 4H), 10.06 (s, 1H), 13.20 (br, 1H). 13C NMR(DMSO-d6, 200 MHz) δ: 28.1, 
36.0, 37.1, 43.1, 95.1, 116.9, 127.6, 128.6, 129.5, 130.2, 130.5, 132.1, 133.9, 157.5, 
161.1, 164.9, 167.2.  
4-[5-(4-Nitro-phenyl)-isoxazol-3-yl]-2-tricyclo[3.3.1.10,0]dec-1-ylphenol (29). 
Yield 85%; mp 246-248 °C. 1H NMR(DMSO-d6, 200 MHz) δ: 1.80 (s, 6H), 2.16 (s, 
9H), 6.82 (d, J ) 8.0, 1H), 6.95 (s, 1H), 7.56 (dd, J ) 8.0, J ) 2.0, 1H), 7.72 (d, J ) 2.0, 
1H), 8.01 (d, J ) 9.2, 2H), 8.34 (d, J ) 9.2, 2H). 13C NMR(DMSO-d6, 200 MHz) δ: 
20.7, 29.0, 29.8, 37.1, 38.0, 40.2, 40.5, 46.9, 100.1, 110.3, 117.4, 120.8, 124.5, 
125.6, 126.1, 126.6, 133.1, 156.7, 167.5.  
4-[3-(4-Nitro-phenyl)-isoxazol-5-yl]-2-tricyclo[3.3.1.10,0]dec-1-ylphenol (34). 
Yield 84%; mp 250-253 °C. 1H NMR(DMSO-d6, 200 MHz) δ: 1.81 (s, 6H), 2.13-
2.16 (m, 9H), 6.76 (s, 1H), 6.77 (d, J=8.4, 1H), 7.57 (dd, J=8.4, J=2.0, 1H), 7.70 (d, 
J=2.0, 1H), 8.03-8.07 (m, 2H), 8.32-8.37 (m, 2H). 13C NMR(DMSO-d6, 200 MHz) 
δ: 28.1, 36.0, 37.1, 43.1, 95.1, 116.8, 126.6, 126.9, 128.6, 130.5, 132.0, 148.1, 157.5, 
161.2, 164.9.  
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General Procedure for Reduction of Nitro Compounds. To a solution of nitro 
compound 29 or 34 (1 mmol, 415 mg) in acetic acid (15 mL) is added Zn powder 
(100 mmol, 6.5 g). The suspension is stirred for 2 h at room temperature. The 
reaction mixture is filtered over Celite and concentrated. The crude material is 
dissolved in ethyl acetate (15 mL) and washed with sodium bicarbonate 5% (5 mL), 
brine (5 mL), dried (Na2SO4), and concentrated to afford the crude amino 
compound which is chromatographed on silica gel. 
4-[5-(4-Amino-phenyl)-isoxazol-3-yl]-2-tricyclo[3.3.1.10,0]dec-1-yl-phenol, 
Hydrochloride (30). Yield 72%; mp 189-191 °C. 1H NMR(DMSO-d6, 200 MHz) δ: 
1.83 (s, 6H), 2.07 (s, 3H), 2.20 (s, 6H), 6.83 (d, J ) 8.2, 1H), 7.25 (s, 1H), 7.50-7.56 
(m, 3H), 7.68 (d, J ) 2.2, 2H), 8.04 (d. J ) 8.6, 2H). 13C NMR (CD3OD, 200 MHz) 
δ: 30.6, 38.0, 38.2, 41.4, 53.6, 99.3, 117.7, 120.7, 123.7, 126.4, 126.6, 128.0, 138.2, 
159.9, 165.2, 170.0.  
4-[3-(4-Amino-phenyl)-isoxazol-5-yl]-2-tricyclo[3.3.1.10,0]dec-1-yl-phenol, 
Hydrochloride (35). Yield 80%; mp 149-152 °C. 1H NMR (CD3OD, 200 MHz) 
δ: 1.83 (s, 6H), 2.08 (s, 3H), 2.20 (s, 6H), 6.84 (d, J ) 8.4, 1H), 7.01 (s, 1H), 7.48-
7.66 (m, 4H), 8.05 (d, J ) 8.6, 2H). 13C NMR (CD3OD, 200 MHz) δ: 29.4, 36.9, 
37.0, 40.1, 95.3, 116.6, 118.5, 123.3, 124.5, 124.6, 128.4, 128.8, 128.9, 130.0, 131.8, 
132.0, 132.6, 133.1, 137.2, 159.0, 172.3.  
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Biology 
 
Cell Culture and Culture Conditions. HL60 cells were obtained from the 
American Type Culture Collection (Rockville, MD). Cells were grown in RPMI 
1640 (Gibco Grand Island, NY) containing 10% FCS (Gibco), 100 U/mL penicillin 
(Gibco), 100 mg/mL streptomycin (Gibco), and 2 mM L-glutamine (Sigma 
Chemical Co., St. Louis, MO) in a 5% CO2 atmosphere at 37 °C. The employed 
serum-free medium is constituted by RPMI 1640 and ITS+1 liquid media 
supplement (Sigma). ITS+1 liquid media supplement contains 0.5% delipidated 
bovine serum albumin, 10 g/mL insulin, 5.5 g/mL transferrin, 4.7 g/mL linoleic acid, 
and 2 mM L-glutamine (Sigma). 
 
Cytotoxicity Assays. To evaluate the number of live and dead cells, cells were 
stained with trypan blue and counted on a hemocytometer. Cells that showed trypan 
blue uptake were interpreted as nonviable. 
 
Morphological Evaluation of Apoptosis and Necrosis. Drugs effects on apoptosis 
and necrosis were determined morphologically by fluorescence microscopy after 
labeling with acridine orange and ethidium bromide. Cells (2 × 105) were 
centrifuged (300g), and the pellet was resuspended in 25 L of the dye mixture. An 
amount of 10 µL of the mixture was placed on a microscope slide, covered with a 22 
mm2 coverslip, and examined in oil immersion with a 100× objective using a 
fluorescence microscope. Live cells were determined by the uptake of acridine 
orange (green fluorescence) and exclusion of ethidium bromide (red fluorescence) 
stain. Live and dead apoptotic cells were identified by perinuclear condensation of 
chromatin stained by acridine orange or ethidium bromide, respectively, and by the 
formation of apoptotic bodies. Necrotic cells were identified by uniform labeling 
with ethidium bromide. 
 
 122 
Determination of Apoptosis by Annexine V. Cells (1 × 106) were washed with 
PBS and centrifugated at 200g for 5 min. The cell pellet was suspended in 100 µL of 
staining solution containing annexine-V-fluorescein labeling reagent (Annexine-V-
Fluos Staining Kit, Roche Molecular Biochemicals, Mannheim, Germany) and 
incubated for 15 min at 20 °C. Annexine V positive cells were evaluated by 
fluorescence microscopy and flow cytometry. 
 
Flow Cytometric Analysis of Cell Cycle Distribution. The effects of the most 
active compounds of the series on cell cycle distribution were studied on K562 cells 
(myeloblastic leukemia) by flow cytometric analysis after staining with propidium 
iodide. Cells were exposed 24 h to each compound. After treatment cells were 
washed once in ice-cold phosphate buffered saline medium (PBS, Sigma) and 
resuspended at 1 × 106 mL in a hypotonic fluorochrome solution containing 
propidium iodide (Sigma, St Louis, MO) 50 µg/mL in 0.1% sodium citrate plus 
0.03% (v/v) nonidet P-40 (Sigma). After 30 min of incubation, the fluorescence of 
each sample was analyzed as single-parameter frequency histograms by using a 
FACScan flow cytometer (Becton Dickinson, San Jose, CA). The distribution of 
cells in the cell cycle was analyzed with the ModFit LT3 program (Verity Software 
House, Inc.). 
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